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Abstract 
 
 
Fingolimod is a Multiple Sclerosis treatment licensed in Europe 
since 2011. Its efficacy has been demonstrated in three large 
phase III trials, used in the regulatory submissions throughout the 
world. As usual, in these trials the inclusion and exclusion criteria 
were designed to obtain a homogeneous population, with 
interchangeable characteristics in the different treatment arms. 
Although this is the best strategy to achieve a robust answer to 
the investigation question, it does not guaranty the treatment 
efficacy in the clinical practice, since in the real world there are 
concomitant treatments, comorbidities, adherence and 
persistence challenges. But, to make informed treatment decision 
for a real life patient, we need to have evidence of the treatment 
efficacy, what has been called treatment effectiveness. This work 
aims to review fingolimod effectiveness, using as source of 
information abstracts, posters and manuscripts. This unorthodox 
strategy was developed because more than half of the published 
experience with fingolimod is still on abstracts and posters. Only a 
small part of the studies reviewed are already published in peer 
reviewed journals. Fingolimod seems to be, at least, as effective 
and safe as it was on clinical trials, and with its long term 
experience no new safety signals were observed. In the 
Portuguese hospital perspective, early treatment with fingolimod 
is expected to result in better clinical outcomes associated with a 
more efficient healthcare resources allocation. 
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Palavras-chave 
 
Fingolimod, esclerose múltipla, evidência do mundo real, prática 
clínica 
Resumo 
 
O fingolimod é um tratamento para a Esclerose Múltipla aprovado 
na Europa desde 2011. A sua eficácia foi demonstrada em três 
grandes ensaios clínicos de fase III, cujos resultados foram 
usados para as submissões regulamentares em todo o mundo. 
Como é habitual, nestes ensaios os critérios de inclusão e 
exclusão foram desenhados para obter uma população 
homogénea, com características intermutáveis nos diferentes 
braços de tratamento. Apesar de esta ser a melhor estratégia 
para obter uma resposta robusta à pergunta de investigação, não 
garante a eficácia do tratamento na prática clínica, uma vez que 
no mundo real existem tratamentos concomitantes, 
comorbilidades, e dificuldades de adesão e persistência no 
tratamento. Mas, para poder fazer uma decisão terapêutica 
informada para um doente de vida real, precisamos de ter 
evidência da eficácia do tratamento, qye tem sido também 
chamada de efetividade do tratamento. Este trabalho tem como 
objetivo rever a efetividade do fingolimod, usando como fontes de 
informação resumos, pósteres e artigos. Esta estratégia pouco 
ortodoxa foi usada pois mais de metade da experiência com 
fingolimod ainda só está publicada através de resumos e 
pósteres. Apenas uma pequena parte dos estudos revistos estão 
já publicados em jornais e revistas científicas revistas pelos 
pares. Esta revisão sugere que o fingolimod é, pelo menos, tão 
eficaz e seguro quanto o foi nos ensaios clínicos, e os seus 
dados de longo prazo não vieram demonstrar novos sinais de 
segurança. Numa perspectiva dos hospitais Portugueses 
pertencentes ao Sistema Nacional de Saúde, o tratamento 
precoce com fingolimod resulta em melhores resultados clínicos 
associados a uma melhor utilização dos recursos disponibilizados 
para a saúde. 
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1.  Introduction 
 
Multiple Sclerosis (MS) is a chronic auto-immune disease of the Central Nervous System 
(CNS), characterized by inflammation and neurodegeneration, with clinic manifestations in 
the motor, sensory and cognitive domains1.    
Multiple sclerosis is still a disease with unknown etiology, which incidence is greater 
for females, Caucasians and people living at higher latitudes. The first symptoms usually 
appear between 20 and 40 years of age.2–5  MS affects 6,000 Portuguese6,7 and 2.5 million 
people in the world.8 MS is serious and potentially debilitating, affecting young and middle-
aged adults in the prime of their lives. It may impact both the life span and the quality of life 
of the affected individual by increasing overall mortality risk as well as risk of ambulatory 
disability. MS is the main non-traumatic cause of neurologic morbidity in young and middle-
aged adults.9–11 Fifty percent of MS patients will need walking aid in the first 15 years of the 
disease.11  
Relapse Remitting Multiple Sclerosis (RRMS) is the most common phenotype (85% of 
MS patients) and the actual therapeutic landscape gives some hope to these patients with 
improved quality of life.12,13 Most current Disease Modifying Treatments (DMTs) for MS 
primarily target the immunological inflammatory component of the disease without acting 
directly on the CNS; such DMTs have been shown to be only partially effective. 
Multiple sclerosis was traditionally considered a white matter disease, in which auto-
reactive T cells passed through the Blood-Brain Barrier (BBB) to the CNS promoting chronic 
inflammation. This focal lesions, with time, result in irreversible damage with axonal and 
neuronal loss. These lesions are usually perivascular, well defined in space, with a clear 
frontier between damaged and intact tissue 14–16.  
A growing body of evidence, from histopathology and imaging, suggests that MS lesions 
are not restricted to these focal lesions, but they are spread out in the whole CNS. The 
diffuse damage in MS is not visible through conventional Magnetic Resonance Imaging (MRI) 
techniques. It is usually located more than 1cm away from the edge of a focal lesion and can 
be observed in grey matter, white matter and in normal-appearing white matter17–20. The 
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chronic demyelination of the neurons, results in axonal damage and loss, which ultimately 
ends in loss of function for the MS patient21. 
The pathological hallmark of MS is the plaques, which are focal demyelinated white 
matter lesions. These lesions are usually very easy to identify in histology or imaging studies 
because they are normally round or ovoid, located in a perivascular region and have a clear 
frontier between damaged and healthy tissue. They can be found in periventricular white 
matter, cerebellum and brain stem, but they also occur in optic nerves and spinal cord. 
These plaques are inflammation focus, with presence of astrocytes, macrophages and 
lymphocytes promoting primary demyelination causing axonal and matrix damage and 
ultimately glial scarring18,19. In early stages of MS remyelination is very frequent, more in the 
subcortical than in the periventricular region, but it decreases with the evolution of the 
disease22. These active lesions evolve sometimes to being chronic and inactive, with far less 
cells and inflammation and no evidence of demyelination, appearing in the MRI T1 images as 
hypointense lesions – black holes14. 
The grey matter focal lesions have a different histopathology from the white matter 
lesions and are difficult to distinguish with conventional MRI techniques14. They are less 
inflammatory and can be the result of axonal damage in the normal-appearing white matter. 
In these lesions is common to find macrophage-associated demyelination, activated 
microglia, neuronal apoptosis and, in many cases, meningeal inflammation14,23,24 and are less 
associated with extensive immune cell influx, complement activation and blood-brain barrier 
leakage than in the white matter lesions25.  
In the normal-appearing white matter there is also evidence of some MS activity 
resulting in diffuse damage26.   This tissue is more than 1cm away from a plaque’s edge and 
is microscopically normally myelinated, with some unusual characteristics like the presence 
of macrophage, demyelination, gliosis and small round cell infiltration. Activated astrocytes 
and microglia are also frequently present14. Axonal density is decreased, comparing with 
normal white matter, and this may be due to axonal damage in focal lesions or due to an 
independent process27,28.  
This disease has a profound impact in patients and their families, reducing their Quality 
of Life (QoL)29,30  and life expectancy, but also increasing the morbidity10. MS also has a big 
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impact on society, not only through high health care costs9, but also because 50% of MS 
patients with a 3.0 score in the Expanded Disability Status Scale (EDSS) are unemployed11. 
Multiple sclerosis represents a big economic burden for the National Health Systems. 
The pharmacotherapy (symptomatic relief treatments and long term treatment with DMTs), 
hospitalization, rehabilitation and the social cost of work absenteeism and early retirement 
contribute to the economic burden of the disease.9,31 In Portugal there are about 2,694 
patients treated with interferon beta (IFNβ)32 and it is estimated that about 30% are poor 
responders and can benefit from second-line treatment.33 Fingolimod treatment costs may 
be seen as an obstacle to treatment escalation, despite the fact that early initiation of 
fingolimod may impact favourably on long-term clinical outcomes.34,35 This analysis aimed to 
assess if the early switch from IFNB to fingolimod impacts MS clinical outcomes and 
promotes better resource utilization in a Portuguese hospital perspective. 
Unfortunately a cure for MS does not exist yet, but a few treatments are used to modify 
the natural course of the disease. Every Disease Modifying Treatment (DMT) goal is to 
achieve a state of full Non Evidence of Disease Activity (NEDA-4), which comprises absence 
of relapses, disability progression, MRI activity and brain volume loss.  
Fingolimod is a DMT used to reduce the progression of the disease and thus improve 
patient’s quality of life. It’s a small lipophilic molecule, with a novel mechanism of action, 
which seems to act both through its peripheral and central actions. Peripherally, fingolimod 
reduces the focal damage 15,16,36 by reducing  the entry of pathological  lymphocytes into the 
CNS and reduces diffuse damage, by its direct actions on the CNS17,18,20,36,37,  reducing the 
activation of pathogenic astrocytes. Through this two independent mechanisms, the central 
effects of fingolimod are also supported by the efficacy results on relapses, MRI activity, 
disability and brain volume loss.38–42 In a Post-hoc analysis of  FREEDOMS and  FREEDOMS II 
(patients with high disease activity despite receiving a DMT in the year before the study), 
fingolimod showed to reduce the 4 key measures of disease activity.43 (Figure 1) In 
FREEDOMS, after 2 years, the likelihood of achieving the 4 parameters of non-evidence of 
disease activity with fingolimod was more than 4-fold higher vs placebo.44 Furthermore, the 
extension phases of fingolimod trials showed that there is a significant clinical benefit of 
initiating the treatment earlier34 and that fingolimod efficacy endures in long term 
treatments,35 which is of utmost importance for a chronic disease like MS. 
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Figure 1. FREEDOMS and FREEDOMS II pooled results at 24 months in patients with high disease activity 
despite receiving a DMT in the year before the study
43
 
 
 
Fingolimod achieved a significant reduction in the Annualized Relapse Rate (ARR) in all 
trials. In patients with the same characteristics as the EU  label requires to start fingolimod 
treatment, with high disease activity despite receiving a DMT in the year before the study, 
fingolimod achieved a 61% reduction in ARR vs IFNβ-1a.41,45  Patients that were treated for 1 
year with IFNβ-1a and switched to fingolimod, have seen its ARR reduced by 46% 34 and the 
ARR remained low after 5 years of treatment.46 
Fingolimod reduced  T1Gd
+ enhanced lesions by 82% in FREEDOMS, and in 
TRANSFORMS and  its extension achieved a 80% reduction in T1Gd
+ lesions in patients who 
had high disease activity despite receiving IFNβ-1a IM in the year before study.34,38 The 
effect on  T1Gd
+ lesions was sustained over 4 years in FREEDOMS and its extension.47 
In FREEDOMS fingolimod reduced the disability progression confirmed at 6 months by 
37% 38 and in LONGTERMS the EDSS score remained stable over 5 years.46  
Fingolimod demonstrated to reduce the rate of brain volume loss by 32% (p<0.001), 
35% (p<0.001) and 33% (p<0.05) in 3 phase III trials, involving a total of 3,647 patients. 38,42,48 
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Results from the extension of these studies,34,47   and results of seven years from the 
phase II study,49 have shown that fingolimod provides a sustained treatment effect, with 
improved clinical and MRI outcomes, and a tendency of brain atrophy curves from patients 
treated with fingolimod to resemble the ones from healthy individuals. 
Fingolimod most frequent adverse effects are cardiovascular effects, liver toxicity and 
lymphopenia. Transient bradycardia, frequently asymptomatic, slight increase in blood 
pressure and small persistent extension of QT interval are the main cardiovascular effects. 
First degree AV block may occur in the first dose, but it’s usually transient and do not require 
pharmacologic intervention. The liver toxicity occurs mainly in the first months of treatment 
and requires monitoring. The laboratory values, after interrupting the treatment, revert 
spontaneously to baseline values after a few weeks. Lymphopenia is a pharmacodynamic 
effect of fingolimod and only requires treatment interruption if lymphocyte counts are 
<200/μL. Macular oedema has a very low incidence and after treatment interruption reverts 
spontaneously.  Respiratory and serious herpetic infections were more frequent with 
fingolimod. Malignancies occurred with the same incidence in all treatment arms. (Table 1) 
38,50 
Fingolimod is approved in the USA since 2010 and in Europe since 2011, with some 
differences in the target label population. Whereas in the USA fingolimod may be used in 
first-line patients, without any restrictions in terms of disease severity, in Europe fingolimod 
can only be used in first-line in patients with severe and rapidly evolving disease.  
Nowadays, a new treatment has not only to prove its effectiveness, safety and quality, 
but it has also to prove its cost effectiveness.  In Portugal, probably in a more exuberant way 
than in other European countries, cost has been a serious issue for all new treatments. Thus 
it is important to prove that, in the Portuguese hospital perspective, using drugs with an 
higher unit price than the drugs already used, may be in the long run more cost-effective 
than using less expensive, but less efficacious drugs.  
Fingolimod has already a significant experience in clinical practice, with more than 
104,700 patients treated and more than 172,500 patient-years of exposure. 51 In this setting, 
a review of its efficacy and safety in the clinical practice is due, to assess how the drug 
behaves in the real world, and what impact does it have in patients’ lives.  
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Table 1. Adverse events in FREEDOMS38 
Adverse events GILENYA 0.5 mg N=425 (%) Placebo N=418  (%) 
Influenza viral infections 13 10 
Herpes viral infections 9 8 
Bronchitis 8 4 
Sinusitis 7 5 
Gastroenteritis 5 3 
Tinea infections 4 1 
Bradycardia 4 1 
Headache 25 23 
Dizziness 7 6 
Paresthesia 5 4 
Migraine 5 1 
Diarrhea 12 7 
Asthenia 3 1 
Back pain 12 7 
Alopecia 4 2 
Eczema 3 2 
Pruritus 3 1 
ALT/AST increased 14 5 
GGT increased 5 1 
Weight decreased 5 3 
Blood triglycerides increased 3 1 
Cough 10 8 
Dyspnea 8 5 
Depression 8 7 
Vision blurred 4 1 
Eye pain 3 1 
Hypertension 6 4 
Lymphopenia 4 1 
Leukopenia 3 <1 
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2. Fingolimod 
Fingolimod was initially investigated as a potential immunosuppressant for kidney 
transplantation, but the results from a Phase III clinical trial disappointed.52,53 Fingolimod 
was not as immunosuppressive as it was needed in a transplantation setting. This led to it 
being further investigated as a new MS treatment. 
Fingolimod is the lead compound in a new class of MS treatments and represents an 
important therapeutic advance. Its unique mode of action targets both the immune and 
central nervous systems which explains its efficacy in reducing the disease activity. 
Fingolimod is rapidly phosphorylated in vivo by sphingosine kinases, 54,55
 
to its 
phosphorylated metabolite, an analogue of sphingosine 1-phosphate (S1P). Fingolimod-
phosphate exerts its action through its interaction with S1P receptors. 
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2.1. Sphingosine 1-phosphate receptor modulation 
Sphingosine 1-phosphate (S1P) receptors are G-protein coupled receptors distributed 
throughout the body 37 and are involved in the regulation of lymphocyte recirculation, 
neurogenesis, neural cell function, endothelial cell function, vasoregulation and 
cardiovascular development.56  Fingolimod is metabolized by Sphingosine Kinases (SphK) to its 
phosphorylated form, 57,58 which binds to S1P Receptors (S1PR) 1, 3 and 4 located on 
lymphocytes. After crossing the blood-brain barrier acts on S1PRs 1, 3 and 5 located on CNS 
cells. Fingolimod phosphate may act as an agonist or a functional antagonist depending on 
the receptor subtype and its location. 59  
2.2. Immune system 
Fingolimod-phosphate, like S1P, exerts its action by binding to S1PRs, which triggers a 
cellular response. After binding to SP1R, S1P promotes the receptor internalization followed 
by its recycling back to the cellular membrane. Whereas with fingolimod after the 
internalization into the endosomal pathway, the S1PR it’s not recycled to the cellular 
membrane and suffers degradation.60–62 In this way, fingolimod acts initially as a S1PR 
agonist, but after some time, it starts to act as a S1PR antagonist because it induces the 
reduction of S1PR available in cell surfaces. 
In the lymphoid tissues, the S1P gradient is responsible for controlling lymphocyte 
trafficking. S1P concentration, which can be sensed by lymphocytes through its S1PR1, is 
lower in lymphoid tissues and higher on tissues and body fluids. The low S1P concentration 
in the lymph nodes induces S1PR1 up-regulation and, if the lymphocyte does not find an 
antigen in the lymph node, will continue in the direction of higher S1P concentrations, which 
drives it out of the lymph node. However, if an antigen is present, it induces the S1PR down-
regulation. The lymphocyte without the S1PR1 does not sense the S1P concentration, and 
does not follow the higher S1P concentrations. Staying longer in the lymph node allows 
more time to be in contact with the antigen presenting cells and to become activated. 
Activated lymphocytes suffer clonal expansion and S1PR1 are up-regulated again allowing its 
egress from the lymph nodes.37,58,63–66 
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When fingolimod is present, the induced down-regulation of S1PR1, turns T-
lymphocytes insensitive to the egress signal provided by S1P gradient. This results in T-
lymphocyte retention in the lymph nodes, and subsequent reduced number of T cells in 
lymph and blood. In MS patients, this means that auto reactive T cells are in lower numbers 
in the blood stream and thus avoiding its migration into the CNS where they would promote 
focal damage, which translates clinically in reduced relapse and MRI activity. 37,58,63–66 The 
lymphocyte functionality, when inside the lymph nodes, remains almost intact 67 and thus 
fingolimod must be seen as an immunomodulator and not as a pure immunosuppressive. 
Usually less than 2% of lymphocytes are in blood and lymph, 68 so the average 70% reduction 
in lymphocyte numbers in the blood, 37,69  does not bring a significant burden to the lymph 
nodes. 
Fingolimod only has an impact on Naïve (Tn) and Central Memory T cells (TCM), and 
CCR7 expressing B cells. These cells traffic regularly through the lymph nodes and are 
susceptible to fingolimod effects. CCR7 is a lymph node homing receptor, that is not 
expressed by all lymphocytes, and can be used to divide T memory lymphocytes in two 
different subsets, the CCR7+ TCM  that express CCR7 and do not have an immediate effector 
function and the CCR7- Effector Memory T Cells (TEM), that do not express CCR7 and have 
an immediate effector function. 67,70,71 
In MS, most of the autoreactive T cell subsets belong to the TCM population. Over 90% 
of Cerebrospinal Fluid (CSF) T cells are CCR7+ TCM, 72 which suggests its important role in MS 
physiopathology. The proinflammatory Th17 cells,  which are augmented in the CSF and 
inflammatory lesions of MS patients, 70,71 belong mainly to the TCM subset. 73–75 Effector 
Memory T cells (TEM), which do not recirculate to lymph nodes, are tissue resident cells with 
an important immune surveillance role. 76,77 Fingolimod does not have an impact in TEM, but 
reduces drastically Th17 numbers in the bloodstream, 67,70 which can explain both 
fingolimod efficacy in reducing MS activity and the incidence of infections similar to placebo, 
almost as if it does not had an effect in the immune competence of the patient.  
Fingolimod induced lymphopenia results from a redistribution of T cells, and not from 
a cytotoxic effect. Thus the lymphopenia induced by fingolimod is readily reversible upon 
interruption of treatment. After a few weeks, lymphocytes counts return to the normal 
range,78 which can be very important to react to a serious infection.  
10 
 
2.3. Central nervous system79 
2.3.1. S1PRs in the CNS 
All S1PRs are present in the CNS, with the exception of S1PR4. However, the type of 
S1PRs present on different CNS cells is still controversial, given it varies with the cell 
differentiation stage and activation status. Oligodendrocytes express S1PR1 and S1PR5 and 
may also express S1PR3, neurons express S1PR1-3 and may also express S1PR5, and 
astrocytes and microglial cells express all S1P1Rs except S1PR480. S1PR1 and S1PR3 have 
been found to be upregulated in MS lesions81 and one report suggests a disturbance in 
sphingolipid metabolism in MS patients.82  
2.3.2. Blood-Brain Barrier 
Fingolimod seems to have a direct action on the BBB itself. It has been proposed that, 
by functionally antagonizing S1P1 and S1P3 receptors in astrocytes, fingolimod could reduce 
the deleterious effects of increased S1P levels and astrocytes on gap junctions between 
neural cells, thus helping to restore the gap-junctional communication between astrocytes, 
neurons and endothelial cells of the BBB.66,83  Fingolimod activation of S1P1 receptors 
enhances adherens junction assembly and endothelial barrier integrity.54 BBB permeability 
can also be altered by S1PR1 and S1PR3 expressed in cerebral capillaries.84 However, in an in 
vitro model of human pulmonary endothelial cells, fingolimod's enhancement of barrier 
function seemed to be independent of both S1P1R and phosphorylation of fingolimod.85 This 
apparent variability and heterogeneity of vascular beds raises the question of whether 
fingolimod actually alters the BBB function. 
2.3.3. Oligodendrocytes and OPCs 
Oligodendrocyte is the major cell type involved in the remyelination process. 
Fingolimod exerts direct protective effects on oligodendrocytes,86 promoting their survival 
including in situations of serum and glucose deprivation.87,88 Fingolimod promotes 
remyelination via direct interaction with S1PRs on oligodendrocytes89,90, an effect also 
observed in organotypic cell cultures.91 In cultures of human mature oligodendrocytes, low 
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concentrations of fingolimod promote myelin production, stimulate membrane formation 
and enhance process extension, while high concentrations have the opposite effect.87,88 
It is thought that the loss of Oligodendrocyte Precursor Cells (OPCs) within MS lesions 
plays an important role in remyelination failure.92,93 Fingolimod protects OPCs from 
apoptosis induced by growth factor deprivation, inflammatory chemokines and microglial 
activation,94,95 promotes remyelination via direct interaction with S1PRs in OPCs,90 regulates 
OPC differentiation into oligodendrocytes88 and inhibits OPC migration,87,96  although the 
latter effect can be prevented if platelet-derived growth factor is used as a 
chemoattractant.88 However, the remyelination process may fail at several stages of 
oligodendrocyte development, and may be associated to a slow response of astrocytes 
and/or microglial cells to demyelination, regardless of its association to OPC response 
failure.97 
2.3.4. Astrocytes 
Astrocytes are the most abundant cells both in the CNS and in MS lesions.98,99 
Astrocytes promote neuron and oligodendrocyte protection,100 axonal regeneration98 and 
myelination.101 It is thought that astrocytes contribute to MS pathophysiological processes 
through the secretion of Matrix Metalloproteinase (MMP) and BBB disruption, secretion of 
adhesion molecules and chemokines, facilitation of inflammatory cells invasion, and 
secretion of TNFα and lymphotoxin-α, causing oligodendrocytes death and axonal injury. 
Also, astrogliosis and glial scar formation, a feature of chronic MS lesions, may interfere with 
the migration of precursor cells, remyelination and axonal regeneration.102  
Activation of S1PRs leads to astrocyte proliferation, inhibition of inflammatory 
chemokines release81,103,104 and increase in the unphosphorylated form of connexin-43, an 
important protein for neuron survival.105 In astrocytes, fingolimod decreases the production 
of the inflammatory chemokine Monocyte Chemotactic Protein-1 (MCP-1),81  mediates 
neuroinflammation relevant effects,106 promotes migration107 and reduces astrogliosis.83,90 
In an adult rat model of lithium-pilocarpine induced epilepsy, fingolimod decreased 
activation of astrocytes in the hippocampus.108 These effects seem to be mediated by S1PR1, 
and suggest a beneficial neurobiological effect of fingolimod, independent of its 
immunomodulatory mechanism.109 
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2.3.5. Microglial cells 
The primary function of microglia is the maintenance of tissue homeostasis and the 
support of regeneration from the earliest stages in the development of demyelinating 
lesions. Microglia supports remyelination and produces several cytokines and chemokines 
involved in the activation and recruitment of endogenous OPCs to the lesion site, also 
providing trophic support during remyelination.110 
Microglial activation is involved in the neurodegeneration of MS progressive types,3 
and fingolimod inhibits persistent activation of microglial cells after a demyelinating event, 
thus promoting remyelination.111 Moreover, activated microglial cells release 
proinflammatory cytokines known to be involved in neuroinflammation,110 and fingolimod, 
via S1PR1, downregulates the production of interleukin-6 (IL-6), interleukin-1beta (IL-1β) and 
Tumor Necrosis Factor-alpha (TNF-α), while upregulating microglial production of Brain-
Derived Neurotrophic Factor (BDNF) and Glial Cell-Derived Neurotrophic Factor (GCDNF),112 
thus suggesting a direct effect in microglia's neuroprotective actions.113 
Administration of fingolimod to Spinal Cord Injury (SCI) models reduces T-lymphocyte 
infiltration without affecting neutrophil infiltration and microglia activation,114 and in an 
adult rat model of lithium-pilocarpine induced epilepsy, fingolimod reduced microglial 
activation in the hippocampus.108  
Taken together, these data suggest a positive role of fingolimod in microglia and 
consequently in microglia's functions. 
2.3.6. Neuroprotection 
The S1P signalling pathway has neuroprotective and pro-cell survival effects during the 
development phase. S1PRs play a role in neurogenesis and induce proliferation of neuronal 
progenitor cells in cultures from rat embryonic hippocampus,115 and S1PR1-knockout mice 
show defects in neurogenesis, while the double SphK1/2 knockout increases apoptosis in the 
developing nervous system, disrupts neurogenesis and increases embryonic mortality.116 
S1PR1 enhances neurite extension, while S1PR2 inhibits it.117 Given fingolimod only occupies 
S1PR1, having no affinity for S1PR2, it may be speculated that it promotes endogenous 
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repair processes mediated by S1PR1 while inhibiting the detrimental effects mediated by 
S1PR2 activation. 
Within the last few years, both in vitro and in vivo models have provided evidence in 
favour of fingolimod neuroprotection ability. 
Fingolimod may have a neuroprotective action, having a positive role in neurite 
outgrowth and neurogenesis.89 In vitro, fingolimod protects cortical neurons against 
excitotoxic death118 and against oligomeric amyloid beta-induced neurotoxicity, being the 
latter mediated by upregulation of neuronal BDNF levels.119 Fingolimod also decreases 
production of Amyloid-β peptide by neuronal cells.120 In a rat model of Alzheimer Disease 
(AD), fingolimod significantly attenuated the Aβ42-induced learning and memory impairment, 
and prevented hippocampus neuronal damage and caspase-3 activation.121 
Fingolimod has been studied in several variants of Experimental Autoimmune 
Encephalomyelitis (EAE), preventing the development of clinical and histological disease 
when used prophylactically, and reversing its manifestations when administered 
therapeutically after disease onset. Clinical benefits include decreased inflammation,122,123 
electrophysiological anomalies ,124 demyelination and axonal loss, 122,123,125–127 synaptic 
dysfunction128  and dendritic injury,89 while improving axial and radial diffusivity, which 
correlate with clinical scores in EAE mice.127 Genetic knockdown of astrocyte S1PR1 reduces 
EAE values and prevents the development of astrogliosis, inflammation, demyelination and 
neuronal loss in the MOG-EAE model.109 Taken together, these results suggest that 
fingolimod functional antagonism of S1PR1 is effective in EAE. 
In an adult rat model of lithium-pilocarpine induced epilepsy, fingolimod has been 
shown to be neuroprotective by reducing neuronal loss, increasing neuronal nuclei positive 
cells and decreasing Fluoro-Jade B positive cells in the hippocampus.108  
Administration of fingolimod to Spinal Cord Injury (SCI) models shortly after injury, 
significantly increases motor function recovery without affecting the mRNA expression of 
inflammatory cytokines, reduces vascular permeability and astrogliosis, having similar effects 
in severely immuno-compromised SCI model mice.114  
In a Lewis mice model of delayed type hypersensitivity, whose later stages resemble 
MS in that there is damage to CNS components behind an intact BBB, fingolimod has been 
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shown to reduce the CNS inflammatory response, decreasing demyelination and inhibiting 
microglial activity.129 
In a model of experimental cerebral malaria, fingolimod inhibited vascular leakage and 
neurological signs and prolonged survival.130 
Fingolimod has shown preclinical anti-cancer activity in neuroblastoma, acting 
synergistically with topotecan,131 and increases viability and neurogenicity of hippocampal 
neural stem cells after irradiation.132  
However, there is one report in which fingolimod did not promote remyelination in 
cuprizone and lysolecithin models of demyelination,133 suggesting that fingolimod 
remyelination ability depends on the mechanisms leading to demyelination.  
Taken together, these results suggest that fingolimod has direct neuroprotective 
effects in several disease models, and not only in MS. Figure 2 summarizes fingolimod most 
relevant effects on the main cell types of the CNS. 
 
Figure 2. Fingolimod most relevant effects on the main cell types of the CNS 
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2.3.7. Clinical Trials evidence  
The central effects of fingolimod have also been supported by the efficacy results 
demonstrated by clinical trials, showing a significant efficacy in reducing relapse rate, 
disability progression and disease activity as assessed by MRI.38–42,48,49 The confirmed 37% 
decrease in disability progression at 6 months, reported by the FREEDOMS study,38 and the 
significant reduction in inflammatory activity as early as at the second month of treatment40 
are consistent with a mechanism of action that includes direct effects in CNS cells. However, 
the most relevant data from clinical trials that confirms this possibility is the reduction of 
brain volume loss rate, already demonstrated in 3 large studies. In fact, the TRANSFORMS,48 
FREEDOMS38  and FREEDOMS II42 studies, involving a total of 3,647 patients, have shown 
that fingolimod reduced the rate of brain volume loss by 32% (p<0.001), 35% (p<0.001) and 
33% (p<0.05), respectively. The fingolimod-induced reduction of brain volume loss was 
shown to be independent of the presence of inflammatory lesions at baseline - Figure 3.  
 
Figure 3. Fingolimod reduction in brain volume loss is independent of the presence of inflammatory 
lesions at baseline 
 
Results from the extension of these studies,35,47   and results of seven years from the 
phase II study,49 have shown that fingolimod provides a sustained treatment effect, with 
improved clinical and MRI outcomes, and a tendency of brain atrophy curves from patients 
treated with fingolimod to resemble the ones from healthy individuals. 
Despite its side effects, fingolimod shows efficacy, real-world adherence and 
tolerability, and some authors have suggested that it is precisely the differential modulation 
of S1PRs in different cells of the immune, cardiovascular and central nervous systems that 
may be responsible for fingolimod efficacy and side effects,134,135 thus supporting the central 
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effects of fingolimod. Nevertheless, continuous research is warranted, not only to unravel 
fingolimod underlying mechanisms of action but also to determine its long-term effects.  
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3. Fingolimod cost-effectiveness analysis136 
 
3.1. Objective 
The present analysis estimates the cost-effectiveness of early versus delayed initiation 
of fingolimod based on results of the double-blind extension of the TRANSFORMS trial over 
the 4.5-year duration of the core and extension phases. 
 
3.2. Methods 
3.2.1. Model 
This analysis was based on the ARR phase III trial extension. 
A cost-effectiveness model was developed to assess the impact associated with 2 
treatment strategies in MS patients (Figure 4): 34,35,48  
a. early treatment: 4.5 years of continuous treatment with fingolimod;  
b. delayed treatment: 1 year of treatment with IFNβ followed by 3.5 years of 
treatment with fingolimod. 
 
 
Figure 4. TRANSFORMS and extension study design. MRI – magnetic resonance imaging. 
a
The optional 
extension phase continued until all the patients either discontinued or were transferred to the 
LONGTERMS study 
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The model calculates the number of relapses associated with the different treatment 
strategies, the total treatment costs, and the cost per relapse avoided. 
3.2.2. Perspective 
A Portuguese National Healthcare System (NHS) hospital perspective was adopted 
addressing only direct medical costs: drug acquisition, monitoring and relapses’ treatment.  
3.2.3. Time Horizon 
The time horizon is 54 months (4.5 years): 1 year of TRANFORMS core phase and 3.5 
years of TRANSFORMS extension phase. 34,35,48 
3.2.4. Data Sources 
This model used the phase III 12-month core and 42-month extension phases of the 
TRANSFORMS trial to compare cost-effectiveness of continuous fingolimod therapy vs IFNβ-
1a for 1 year followed by fingolimod therapy. The complete methods of the TRANSFORMS 
study program have been previously described. The TRANSFORMS core study enrolled 
patients aged 18 to 55 years with a diagnosis of relapsing–remitting MS and who had 
experienced at least 1 documented relapse in the 2 years before randomization.  
In the core study, patients were randomized to receive 1 of 3 treatments: 0.5 mg/d 
oral fingolimod, 1.25 mg/d oral fingolimod, or 30 µg/wk IM IFN-β1a. During the extension 
phase, patients who had received fingolimod during the core stage continued to receive the 
same assigned dose, whereas patients who had originally received IFN-β1a were randomized 
to receive either 0.5 or 1.25 mg/d oral fingolimod. 
Of the 1292 patients randomised in the Core phase, 1,030 entered the extension phase 
of TRANSFORMS and a total of 772 patients completed the 54 months of treatment. The 
aggregate ARR at end point was 0.17 in the early 0.5-mg/d fingolimod group, and 0.27 in the 
delayed group, resulting in a 39% reduction in ARR with early treatment with fingolimod 
versus delayed fingolimod after IFN-β1a (p<0.001).35 A real-world, observational, 
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retrospective analysis determined that in patients newly initiating IM IFN-β1a therapy, the 
relapse rate over the previous year was 0.77.137 On the basis of this rate of relapse in the 
untreated population, the number of relapses avoided with early treatment with fingolimod 
was calculated. 
Drug acquisition costs for fingolimod were obtained from Infarmed’s Approval Report for 
Gilenya®,138 while for IM IFN-β1a these were obtained using Avonex® 2013 acquisition cost 
listed in the Portuguese web-based pricing catalogue for hospitals.139 To obtain the net drug 
acquisition cost, prescribing information was used to determine the number of doses per 
package and the number of packages used per year.50,140 The model did not include product 
rebates, discounts, or patient co-pays or co-insurances, and assumed all patients were 100% 
adherent to treatment. Drug acquisition costs are presented in Table 2.  
 
Table 2. Drug acquisition costs 
Medication Fingolimod IFNβ-1a 
Posology 0.5 mg / day 0.03 mg / week 
Unit cost (€) 1,648.43 778.10 
Annual cost (€) 21,488.46 10,115.30 
 
Monitoring requirements differed between treatments, and were based on each 
agent’s product prescribing information, clinical guidelines and empirical clinical practice, 
validated by an experts’ panel. On the basis of prescribing information for fingolimod, all 
patients new to fingolimod therapy were assumed to undergo a 6-hour in-office observation 
for signs and symptoms of bradycardia after the first dose and an ECG before receiving the 
first dose and at the end of the 6-hour first-dose observation period. All patients new to 
fingolimod must have 6 Complete Blood Cell counts (CBC) and 6 liver function test based 
during the first year. One ophthalmologic visit was also included in the year 1 fingolimod arm 
per the monitoring recommendations of the package insert. 
Unit monitoring costs were obtained from 2 different sources of information: 
1. both the 6-hour in-office observation and the outpatient consultation costs were 
derived from the database for Analytical Accounting of the Portuguese Hospitals 
for 2009 and; 141 
2. procedure costs were obtained from the Portuguese Diagnosis Related Groups 
tariff (Portaria n.º 20/2014).142 
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The cost of other potential monitoring requirements for patients at high risk, such as 
dermatology visits and pregnancy tests, and tests commonly required for diagnosis of MS, 
were not included in the model. Similarly, costs of extended first-dose monitoring for 
patients receiving fingolimod who had some pre-existing conditions were not included 
because of lack of clarity on the prevalence of such patient populations. Resource use and 
unit costs considered are included in Table 3. 
 
Table 3. Resource use and monitoring costs 
Monitoring 
Early treatment Delayed treatment 
Unit cost (€) 
FTY year 1 FTY year 2 IFNβ year 1 FTY year 1 
In-office observation 1 0 0 1 615.77141 
Neurologist visit 6 2 2 6 214.26141 
Ophthalmologic visit 1 0 0 1 42.32141 
Complete blood count a 6 2 4 6 4.70142 
Liver function tests b 6 2 3 6 15.10142 
Thyroid panel c 0 0 1 0 17.00142 
MRI d 1 1 1 1 127.90142 
ECG e 3 0 0 3 6.50142 
Total costs (€) 2,209.85 596.02 637.52 2,209.85 – 
FTY – fingolimod; MRI – magnetic resonance imaging; ECG – electrocardiogram; DRG – diagnosis related groups 
a
 DRG 24209; 
b
 DRG  (21140, 21220, 21217, 21935, 21344, 22035, 21665, 24347, 24359); 
c
 DRG (22253, 22925, 
22897, 22900); 
d
 DRG 18010; 
e
 DRG 40301 
 
The estimate on the cost of relapse was derived from a study performed by Mateus et 
al.143 This author estimate the cost of relapses in patients with relapsing–remitting MS based 
on hospitalizations, medications used to treat relapses, ambulatory care and the use of other 
resources. The costs associated with hospitalization and ambulatory care represent around 
95% of total costs, regardless of the level of EDSS.  
Low-intensity relapses were defined as those requiring a physician office visit, 
treatment with symptom-related medication, and a follow-up visit. Medium-intensity 
relapses were defined as those requiring a physician office or emergency department visit, 
treatment with IV methylprednisolone and symptom-related medications, and a follow-up 
office visit or consultations with a physical, occupational, or speech therapist. High-intensity 
relapses were defined as those requiring a physician office or emergency department visit, 
treatment requiring hospital admission, and post discharge services including outpatient 
follow-up, rehabilitation, home health care, skilled nursing facility care, and short-stay 
21 
 
nursing home care, or hospital readmission within 30 days. The relative incidence of each 
relapse severity was obtained from the EVIDENCE (Evidence for Interferon Dose-response: 
European North American Comparative Efficacy) trial.144 
Based on such information, and the potential distribution of patients by EDSS level, the 
cost of a relapse was estimated to be € 5,852.40 per relapse (Table 4). 
Table 4. Relapses’ treatment costs 
Relapses EDSS<3 3.5<EDSS>4,5 5>EDSS>6 EDSS>6,5 Total 
Total cost / relapse143 3,986 5,139 7,212 7,556 – 
% of patients6 25% 30% 25% 20% – 
Estimated cost / relapse (€) 996.50 1,541.70 1,803.00 1,511.20 5,852.40 
EDSS – Expanded Disability Status Scale 
3.3. Results 
Assuming there are 819 patients treated with IFNβ that are poor responders, the early 
treatment with fingolimod resulted in more relapses avoided, 2,211, when compared with 
delayed treatment with fingolimod, 1,843 – an additional 368 relapses avoided. From year 1, 
the number of relapses avoided is higher for early treatment group compared with delayed 
treatment. This difference increases over time (Figure 5). 
 
Figure 5. Number of relapses avoided over 4.5 years with early treatment vs. delayed treatment 
3.3.1. Incremental costs 
The early treatment with fingolimod led to an increase of drug acquisition costs, but 
reduced costs associated to monitoring and relapses’ treatment. The total costs were 
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86,380,820€ for early treatment versus 79,257,091€ for delayed treatment. This represents 
an average incremental investment of 1,933€ per patient per year.  
3.3.2. Cost-Effectiveness Analysis 
The early strategy resulted an incremental cost effectiveness ratio of 19,358€ per 
relapse avoided when compared with the delayed strategy (Table 5).  
After three years, the early treatment with fingolimod is associated with lower costs per 
relapse avoided compared with delayed treatment.  
 
Table 5. Analysis of a cohort of 819 patients in a 4.5 years’ time horizon 
 
Early treatment Delayed treatment Difference 
Medication costs (€) 79,195,729 69,881,108 + 9,314,620 
Monitoring costs (€) 3,518,358 3,552,347 – 33,989 
Relapses’ treatment costs (€) 3,666,733 5,823,635 – 2,156,902 
Total costs (€) 86,380,820 79,257,091 + 7,123,730 
Relapses avoided 2,211 1,843 368 
ICER (€ / relapse avoided) – – + 19,358 
 
The estimated cost per relapse avoided was € 39,063 in the early treatment group 
compared to €43,010 in the delayed group. 
The early treatment strategy had a cost per relapse avoided € 3,947 lower than the 
delayed treatment strategy (Figure 6). 
 
 
Figure 6. Cost per relapse avoided variation over 4.5 years of early treatment vs. delayed treatment   
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4. Fingolimod real world effectiveness 
4.1. Introduction 
Nowadays a new MS drug usually has at least one phase II and two Phase III Clinical 
trials in order to get the required Regulatory Authorities’ approvals. But, as it is commonly 
accepted, Randomized Clinical Trials (RCTs) have a very homogeneous population without 
any big issues in terms of comorbidities and co-medication. This is necessary in order to 
meet the trial’s endpoints, in the shortest timeframe and with the smaller sample size 
possible. However, these perfect patients are rare in the hospitals and more often than not, 
MS outpatient clinics have many patients that although can be treated on-label by the drug, 
have very different characteristics from the trials’ population.  There are also factors 
inherent to treatments, which may influence its application in clinical practice. The 
outcomes of using the drug in a real world setting maybe very different from the ideal 
scenario that happens in clinical trials. (Table 6) 
Table 6. Potential reasons for treatment results being different between clinical practice and 
the clinical trials145 
Study design 
Trial protocol forces uncommon clinical scenarios 
Comparison group does not represent current standard of 
care 
Patient selection 
Biases in the patients who are eligible for a therapy 
Biases in patients who are ultimately treated with the  
therapy 
Therapeutic 
implementation 
Complexity of therapies makes them challenging to 
implement 
Procedural experience of providers influences outcomes 
Environment of the 
healthcare delivery system 
Limited availability of providers or resources 
Inadequate levels of reimbursement 
 
 That’s the reason why it is of utmost importance to share the experiences, present 
abstracts, posters or communications in congresses and publish clinical practice results. 
Furthermore, important drug outcomes, like resource utilization, treatment satisfaction, 
quality of life or other Patient Reported Outcomes (PROs) aren’t usually included in the 
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regulatory trials’ outcomes. Safety issues are also a good reason to share experiences, 
because the causal association between very rare safety events and a drug can only be made 
if everyone makes an effort to report to the Market Authorization Holder and/or Health 
Authorities. When these reports aren’t made, if physicians publish and present posters the 
information will be captured when the pharmacovigilance departments do the scientific 
literature review.  
Efficacy is the treatment result the drug can achieve in clinical trials and effectiveness 
is the result obtained in clinical practice. Efficiency is a third concept, which has gain a lot of 
importance especially in these last years, and it brings the economic factor to the equation, 
where the effectiveness is put in perspective with the economic aspects of using the drug in 
the real setting. 
Real World Evidence, as defined by ISPOR, is data used for clinical, coverage and 
payment decision-making that are not collected in conventional randomized controlled 
trials.146 This kind of data is gaining importance for coverage and payment decisions and its 
need has been rising in last years.146 Several methods of capture this data can be used: 
- Observational studies 
o Prospective 
o Retrospective 
o Cross-sectional 
- Patient registries  
- Surveys 
- Electronic health records 
- Administrative claims data 
 
Although randomized clinical trials are still considered the gold standard, RWE can 
answer questions, which clinical trials haven’t done it. Many physicians don’t consider RWE 
studies as a reliable source of information to serve as basis for therapeutic decisions, but 
some reports suggest that observational studies have a good reproducibility and its results 
have a strong correlation with the results obtained in randomized clinical trials.147–149 
Although there are also reports pointing some differences between RCTs and observational 
trials, these differences can be explained in some cases by confounding factors that were not 
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included in the analysis. 150 Observational studies have been getting increasing importance 
and recognition in comparative effectiveness research.151 
 Observational studies are much closer to clinical practice than RCTs and are less 
expensive to run. These studies can be prospective, if the data will be collected as it occurs, 
by following up the patients; retrospective if the data collected is already registered, in 
clinical charts for instance; or cross-sectional if it is a one-time assessment which collects 
data specific for that moment, much like a photography captures an image in that specific 
moment.  
Registries can be as wide as population based registries, like the ones that exist in the 
Nordic countries,152 or disease specific as MSBase153  or drug specific as the adalimumab 
registry.154 The population based registries have millions of subjects and it’s easy to find 
controls, making the external validity very high, but since they are not drug or disease 
specific important information may not be captured. Treatment and drug registries can be a 
good reliable source of information not only for assessing the effectiveness and safety of a 
drug, but also to do comparative effectiveness analysis, frequently required by health 
technology assessment groups. Registries don’t have a finishing date, like observational 
trials, which can be useful to access drug effects with a considerable delay between 
exposure and outcome, as it is usually the case with malignancies.  
Observational studies and registries both can have bias issues, as indication bias, 
information bias and confounding bias. These situations occur when there is a preference for 
enrolling patients with certain characteristics in one of the treatments, there is information 
easier to detect in one group than in the other, or exists a confounding factor that it is both 
associated with the exposure and outcome. If the bias is well identified, several methods can 
be used to overcome this issue, both in the study design, like new user design155 or excluding 
patients with contraindications for any of the studied drugs,156,157 and in the data analysis, 
like  multivariable adjustment through regression models158,159 or propensity analysis.160 If 
there are unidentified or unmeasured biases only instrumental variable methods can 
diminish its effects,161,162 even though some author argue that these are equivalent, or even 
inferior to standard multivariate adjustment methods.163,164  Study design and the quality of 
data used are, like in RCTs, crucial factors to study validity.  
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Surveys and interviews may also be used to gather subjective patients and physicians 
opinions. Poor recall by subjects, low response rates or intentional misinformation, due to 
the topic sensitivity for instance, are the main limitations of these studies. Additionally, 
interviews also have limitations because they are expensive, do not provide anonymity and 
bias can be unintentionally introduced by the interviewer. 
The use of Electronic health records and Administrative claims data warrants 
generalizability because of the huge number of subjects, it’s usually also associated with 
reduced research costs and faster results. However, these databases have a different 
objective and thus must be used with caution. When doing studies using this data, one must 
be aware that some limitations may be present as lack of data accuracy, measurement error, 
diagnostic error or miscoding, interventions miscoding, undetected cointerventions, missing 
vitals, biometrics and lab values, etc. These databases are particularly useful to research 
drug adherence and persistence, resource utilization and outcomes in rare diseases. In order 
to do comparative studies, statistical methods can be used to match the different treatment 
arms.165 
Fingolimod is approved in the United States of America since 2010 and in Europe since 
2011. It has been used in more than 104,700 patients worldwide and it has an exposure of 
more than 172,500 patient-years.51 Since 2011 we have assisted to a growing number of 
RWE studies presented at congresses and published in peer reviewed journals. I think it is 
important now to take a moment to reflect how the drug has been used in clinical practice 
and what the efficacy outcomes are. 
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4.2. Methods 
A literature search was done to identify fingolimod congress abstracts (2013 and 2014) 
posters and manuscripts (since January 1st 2011) about its use in the clinical practice. The 
databases used were Medline, Embase and Biosis previews. Case reports and studies with 
small samples (less than 8 patients) were excluded as well as publications with data from 
blinded clinical trials, because they were not considered real world data.  
To avoid considering duplicate data an effort has been made to only include in the 
analysis the latest report of each series of patients excluding older abstracts, manuscripts 
with the same pool of patients and outcome measures. Whenever there was available an 
abstract and a published paper the information was extracted from the later. Reviews and 
manuscripts or abstracts reporting subgroup analysis with the same outcomes of the original 
study were also excluded.  
For the safety data analysis, in order to avoid overestimating adverse events incidence 
due to small samples, it was used a cut-off of 500 patients in the cohort. In order to have a 
broader perception of fingolimod safety, it was decided to include in the analysis the five-
year interim results of the LONGTERMS extension study. The search was limited to 
references published after January 1st 2013. 
After selecting the references to include the review, the data was collected using 
Microsoft Excel 2010, version 14.0.7128.5000 (32-bit). In this spreadsheet it was predefined 
to use these columns to fill as needed per study: 
- Status: Processed, Duplicate, Excluded, Accepted 
- File: File number with the PDF 
- Cohort: Identification of the cohort 
- Year 
- Focus: Efficacy, FDO, FTY vs DMTs, FTY vs DMFs, FTY vs NTZ, Neurologist Reported 
Outcomes (NRO),  NTZ switch, Large Open trials, Other, Patient Reported 
Outcomes (PRO), Registry and Safety  
- Number of patients (FTY patients; other therapy patients) 
- Baseline demographics 
- Time since diagnosis of MS (years) 
- Time since onset of symptoms of MS (years) 
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- Percentage of patients with natalizumab (NTZ) as previous treatment (PNTZ) 
- Washout period from NTZ (weeks) 
- Number of NTZ infusions: whenever this number was not reported, it was 
assumed  that the number of infusions was equal to the number of months in 
treatment 
- Baseline ARR: previous 12 months where possible, but other measures also have 
been registered 
- Baseline MRI activity  
- Baseline EDSS  
- Source of data: Registry, Claims database, Observational prospective, 
Observational presumably prospective, Observational retrospective, 
Observational presumably retrospective, Cross-sectional and NA (impossible to 
classify) 
- Mean Follow-up (months)  
- Persistence [Adherence]  
- ARR  
- Relapses  
- Percentage of relapse-free patients 
- MRI  
- MRI activity free  
- EDDS difference  
- EDSS unchanged or improved   
- Percentage of patients free of relapse and EDSS progression  
- Percentage of patients free of relapse and T1Gd+  
- Percentage of patients free of relapse and MRI activity  
- Percentage of patients free of EDDS progression and MRI activity  
- Percentage of patients free of relapse, EDDS progression and MRI activity  
- PRO/Other 
- NRO  
- First Dose Observation (FDO)   
- Comments 
 
In comparative studies (FTY vs DMTs, FTY vs DMF, FTY vs NTZ) and whenever there was 
available subgroup data, the values for each cohort or subgroup were also registered in the 
same cell.  
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Whenever more than one publication was accepted for the same cohort, because they 
were reporting different outcome measures, the data was merged in the same row. 
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4.3. Results 
4.3.1. Publications 
4.3.1.1. Source selection 
The references were identified using several databases. The data was extracted from 
abstracts, manuscripts and posters.  The study references, abstracts, posters and 
manuscripts, were scrutinized to achieve the final pool of references which are included in 
this review.  From the 244 references identified 148 were rejected and classified as: (Figure 
7) 
- Duplicates if it had the same pool of patients, with similar outcomes. The most 
common situation was abstracts or poster presented in different congresses 
where it was possible to observe the growing number of patients in the cohort; 
- Study design if it was a poster or abstract reporting the open study design and\or 
baseline patient demographics; 
- Letter to the editor if it did not report anything new. One Letter to the editor was 
used to complement the information gathered from one cohort, for which the 
original posters\abstracts missed some details; 
- Clinical trials if it was the result reporting of blinded clinical trials; 
- <8 patients if the cohort was small. The cut-off of 8 patient does not have any 
specific rational; 
- Review if it was a review of published results; 
- Subgroup analysis if it was the report of subgroup analysis with the same 
outcome measures as the original work; 
- Without relevant data if it did not have relevant data for the objective of this 
review  
 
For the safety analysis the data was extracted from 9 references representing 7 
cohorts. 
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Figure 7. Selection of studies for inclusion in the overall review. A total of 96 reports were included for 
the overall review and 7 studies for the safety review 
  
4.3.1.2. Patients 
During this work it became clear that physicians’ publication habits were very different 
from country to country and even from region to region. 72 different cohorts with published 
results were identified. Unfortunately is not possible to completely identify in an individual 
manner many cohorts, because there are many publications where the cohort is defined by 
a registry, a network of physicians\clinics, an administrative region, or a few MS centres who 
merge together their data in order to obtain a more robust database. There are published 
results from 23 different countries, and some cohorts are considered Multinational 
whenever more than 2 countries are involved. (Figure 8) 
 
Identified 
244 
Reviewed 
133 
Final 
96 
Duplicates 
111 
Exclusions 37: 
1 Study design 
5 Letter to the editor 
4 Clinical trials 
4 <8 patients 
7 Review 
1 Subgroup analysis 
13 Without relevant data 
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Figure 8. Cohorts studied per nationality 
 
The number of patients per cohort varies wildly, from 8 to 3,641, with a total of 31,199 
patients studied. Each study has an average of 330 patients. Unfortunately, it isn’t possible 
from the data collected to estimate accurately how many unique patients this represents, 
because there is some overlap of different studies, using the same patient pool with 
different inclusion and exclusion criteria, or aggregating data from three different centres 
and in a different study using two of these centres aggregated with another different centre, 
etc.  
In a very conservative approach, the minimum unique patients involved in these 
studies should be 14,582. This was estimated considering for each cohort the patient 
number was equal to the number of patients reported in its biggest study and only 50% of 
patients in multicentre studies were not studied in another study.  The calculation of 
patients for Italy, as an example, is on Table 7. The EPOC study, the only one with less than 
three countries, and not included in the multinationals, reported a maximum number of 976 
patients in 152 USA and 6 Canada centres. So it was considered that USA enrolled 96.2% of 
patients and Canada enrolled the other 3.8%. 
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The maximum number of unique patients is 25,916, which was calculated by summing the 
maximum unique patients in each cohort.  
Table 7. Patient calculation example for Italy 
Cohort Patients Maximum Conservative 
Ferrara, Parma 
Modena, Reggio-Emilia, 
Fidenza and Piacenza 
127 127 127 
Gallarate 32 
 
0 
Gallarate 55 55 55 
iMedWeb registry 106 106 53 
L' Aquila, Pozzilli, Foggia 142 142 142 
L' Aquila, Pozzilli, Foggia 100 
 
0 
Milan 61 61 61 
Milan 37 
 
0 
Multicenter Italy 906 906 453 
Naples 112 112 112 
Orbassano 35 35 35 
Padua 21 21 21 
Rome 55 55 55 
Turin 35 35 35 
Total 1824 1655 1149 
 
Germany, USA and Canada are the countries which enrolled more unique patients in 
these studies, followed by Italy, Japan and Sweden. (Figure 9) 
 
Figure 9. Conservative number of patients enrolled in studies per country 
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4.3.1.3. Study design 
The studies included in this review have different designs and were classified according 
to the source of data. It is not rare to forget to publish the complete information about the 
study design and I have found 11% studies impossible to classify and another 9% studies that 
the reported methodology suggests that is a retrospective or a prospective study, but it is 
not explicit.  Even considering this uncertainty prospective studies dominate, closely 
followed by retrospective studies. Even if the impossible to classify are all prospective 
studies, it would not be enough to reach a 50% share of studies. Registries and claim 
databases represent 13% of the studies. (Figure 10) 
 
Figure 10. Study classification according to source of data 
 
It is also interesting to notice that some study groups do a better utilization of the 
cohort data and publish results focusing in different subjects, thus from 72 cohorts there is a 
total of 95 different studies, resulting in 1.32 published studies per cohort. (Figure 11) 
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Figure 11. Studies in countries with more than one study published by cohort 
 
 
As it was expected Natalizumab switch, First Dose Observation and Efficacy are the 
three favourite themes, but Patient Reported Outcome and First Dose Observation have the 
biggest number of patients. (Figure 12) The category Other was composed of studies 
focusing on:  
- Effect of FTY on macular volume and retinal nerve fibre layer thickness 
- Use of blood lymphocyte count as a biomarker of FTY efficacy 
- FTY influence in changes in frequency and intensity of pre-existing headaches 
- Impact of FTY on comorbid migraine 
- Brain volume changes 
- Cognition 
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Figure 12. Cohorts and patients stratified by study main focus 
4.3.1.4. Type of publications 
Being fingolimod a recently approved treatment, the usual approach of doing a 
literature review considering only published papers would result in a small source of data, 
consciously I decided to do an unorthodox work, including abstracts, posters and 
manuscripts. This resulted in 96 publications to review, dated since 2012. (Figure 13) 
 
Figure 13. Growing number of publications per year 
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 The big proportion of abstracts is due to the correspondent posters being unavailable 
online. There were only two exceptions, one abstract from a Russian manuscript166 and from 
a Polish manuscript167, which only the abstract was available in English and one abstract 
from a French thesis168, which I did not succeed in obtaining a copy of the full thesis. As far 
as I am aware I searched everything that was available on the databases in Portuguese, 
Spanish, English and French languages. (Figure 14) 
  
Figure 14. Publications reviewed 
 
Only countries with a substantial amount of published work have published papers in 
peer reviewed journals, being Kuwait, Poland and Russia the only exceptions. (Figure 15) 
 
Figure 15. Publications by country 
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4.3.2. Baseline characteristics 
Baseline characteristics are summarized in Table 8 
 
 
   
3
9 
Table 8. Baseline characteristics 
Cohort Country Focus Patients 
Time since 
diagnosis of 
MS (years) 
Patients with 
NTZ as 
previous 
treatment 
Washout 
period from 
NTZ (weeks) 
NTZ 
infusions 
Baseline ARR 
(previous 12 
months) 
Baseline 
MRI activity 
Baseline 
EDSS 
Source 
of data 
FU 
(months) 
REAL169 Argentina Registry 48 9.1 
     
2.7 Reg 8.5 
Multiple Sclerosis 
Treatment Registry170 
Austria 
FTY vs 
NTZ 
312 (NTZ 1208) 
8.9 (NTZ 
7.8) 
54.2% 
  
1.8 (NTZ 2.3) 
 
2.6 (NTZ 3.2) Reg 
21.5 (NTZ 
35.7) 
São Paulo171 Brazil FDO 180 
       
R 
 
Gilenya* Go 
Program(TM)172 
Canada PRO 1700 
       
P 
 
Multiple Sclerosis 
Registry Denmark173 
Denmark FDO 496 10.6 32.3% 
  
0.37 (PNTZ 
patients 0.46)   
R > 3 
Alsace174 France 
NTZ 
switch 
59 
 
100% 6.8 
    
R 7 
Alsace175 France Efficacy 290 
      
3.6 R 12 
Bordeaux176 France FDO 24 
       
P 3 
ENIGM177 France 
NTZ 
switch 
333 
 
100% 
17 (55% 
patients 
without MP 
or other 
DMTs) 
31 
  
3.7 (pre-NTZ 
3.6; post-
NTZ 3.6) 
P 6 
GRACE178 France PRO 198 8.1 
   
1.6 
 
2.6 P 
 
Reims168 France Efficacy 66 
       
P 
11 (51.5% 
>12 
months) 
Dresden179 Germany FDO 36 4 
      
P* 
 
Munich, Bochum, 
Marburg180 
Germany 
NTZ 
switch 
33 
 
100% 
 
31.8 0.2 (pre-NTZ 2.5) 
 
3.2 (pre-NTZ 
3.1) 
R 20.3 
NeuroTransConcept181 Germany 
FTY vs 
NTZ 
190 (NTZ 239) 
9.89 (NTZ 
9.15)    
0.34 (NTZ 0.42) 
 
2.3 (NTZ 3.3) R 12 
PANGAEA182–184 Germany 
Large 
open 
trials 
3641 (PEARL 
active 457; 
PEARL inactive 
1248) 
8.2  (PEARL 
active 6.7; 
PEARL 
inactive 7.3) 
18.4% 
31.9% 
Patients 
with WO 
<12 
 
1.5 (PNTZ 0.9; 
PEARL active 
1.23; PEARL 
inactive 0.37) 
 
3 (PEARL 
active 2.60; 
PEARL 
inactive 
2.20) 
P <24 
START185 Germany FDO 1640 
      
2.8 P 
 
Athens186 Greece 
NTZ 
switch 
60 
 
33.3% 
     
NA 
>12 (MP 8-
12) 
Ramat-Gann187 Israel Efficacy 110 14.6 
     
3.8 R 20 
Tel-Aviv188,189 Israel Other 30 
    
1.2 
 
0.4 increase 
in previous 
12 months 
P 12 
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Cohort Country Focus Patients 
Time since 
diagnosis of 
MS (years) 
Patients with 
NTZ as 
previous 
treatment 
Washout 
period from 
NTZ (weeks) 
NTZ 
infusions 
Baseline ARR 
(previous 12 
months) 
Baseline 
MRI activity 
Baseline 
EDSS 
Source 
of data 
FU 
(months) 
Ferrara, Parma 
Modena, Reggio-Emilia, 
Fidenza and Piacenza190 
Italy Efficacy 127 10.7 30.7% 18 
 
1.2 
65,4% 
(31.5% 
T1Gd+) 
3.1 (PNTZ 
patients 3.6) 
P* 10 
Gallarate191 Italy Other 55 12.5 21.8% 
  
1.7 in previous 24 
months   
NA 12 
Gallarate192 Italy 
NTZ 
switch 
32 
 
100% 15.6 21 
   
NA 
73.3% 
patients 
with >6 
months 
iMedWeb registry193 Italy 
NTZ 
switch 
106 (DMTs 106) 
13.15 
(DMTs 
12.83) 
100% 
 
26.41 
(DMTs 
19.42) 
  
3.79 (DMT 
3.95) 
R 
 
L' Aquila, Pozzilli, 
Foggia194 
Italy Efficacy 142 
 
19.7% 
     
NA 15 
L' Aquila, Pozzilli, 
Foggia195 
Italy 
FTY vs 
NTZ 
100 (NTZ 100) 
    
1.2 (NTZ 1.9) 
78% of 
patients 
(NTZ 90%) 
2.6 (NTZ 2.9) P 12 
Milan196 Italy 
NTZ 
switch 
61 
 
100% <52 
 
1.2 (0.15 on NTZ; 
1.2 WO period)  
EDSS 
increase 
0.43 (0.15 
on NTZ; 0.43 
WO period) 
R* >6 
Milan197 Italy 
FTY vs 
NTZ 
37 (NTZ 160) 
11.5 (NTZ 
10.1)    
1.2 (NTZ 1.3) 
 
2.1 (NTZ 2.5) P >12 
Multicenter Italy198 Italy FDO 906 8.56 24.3% 
  
1.36 
 
3.06 P 3.14 
Naples199 Italy FDO 112 
       
P* 
 
Orbassano200 Italy 
NTZ 
switch 
35 (T 19; NT 24) 
  
>12 
    
R 
 
Padua201 Italy 
NTZ 
switch 
21 10.7 100% 12 
   
2.9 P* 
 
Rome202 Italy FDO 55 
      
1.7 P 
 
Turin203 Italy Other 35 11.3 
      
P 6 
Multicenter Japan204 Japan Registry 837 9.3 
   
0.98 
  
Reg 
 
Tokyo205 Japan Efficacy 44 13.1 0% 
     
R 
 
Kuwait city206 Kuwait Efficacy 76 7.82 2.6% 
  
13.2% relapse 
free 
22.4% MRI 
activity free 
2.93 R 18.5 
MS registry Kuwait207 Kuwait Efficacy 175 7.2 5.7% 
  
32.6% relapse 
free 
23.3% MRI 
activity free 
2.6 Reg 21.7 
FIRST208 Multinational FDO 2417 
 
10.5% 
  
1.1 
 
2.4 P 4 
LONGTERMS209,210 Multinational Safety 
        
P 
 
   
4
1 
Cohort Country Focus Patients 
Time since 
diagnosis of 
MS (years) 
Patients with 
NTZ as 
previous 
treatment 
Washout 
period from 
NTZ (weeks) 
NTZ 
infusions 
Baseline ARR 
(previous 12 
months) 
Baseline 
MRI activity 
Baseline 
EDSS 
Source 
of data 
FU 
(months) 
MSBase Registry211 Multinational 
NTZ 
switch 
89 12.8 100% 
95% with 
WO < 4 
months; 2.6 
months 
 
0.26 
 
4 R 7.6 
MSBase Registry212 Multinational 
FTY vs 
NTZ 
171 (NTZ 407) 
9.5 (NTZ 
9.4)    
1.29 (NTZ 1.53) 
 
3 (NTZ 3.5) P 12 
MSBase Registry213 Multinational 
FTY vs 
DMTs 
148 (DMTs 379) 
7.2 (DMTs 
7.3)    
1.3 (DMT 1.2) 
 
2.5 (DMT 
2.5) 
P 11 
PASSAGE214 Multinational 
Large 
open 
trials 
1596 8.56 19.6% 
  
1.0 
 
2.72 P 9 
Warsaw167 Poland Efficacy 11 >3 
      
NA 12 
Coimbra215 Portugal 
NTZ 
switch 
29 10.4 100% 9.2 28.7 0.5 
 
2.7 R 17.4 
Guaynabo216 Puerto Rico Efficacy 50 
       
R 12 
Guaynabo217 Puerto Rico FDO 25 
       
R 6 
Moscow166  Russia Efficacy 11 
       
NA 
 
Prešov218 
Slovak 
Republic 
NTZ 
switch 
9 
 
100% 3.3 24.1 0 (pre-NTZ >2) 
  
NA 
 
Alicante219 Spain 
NTZ 
switch 
8 11.1 100% 12 29.4 
pre-NTZ 1.6; pre-
FTY 0.13;  
2.4 P* 9.35 
Granada220 Spain FDO 42 9 
      
R 
 
Hospital Ntra Sra Valme, 
Seville221 
Spain 
NTZ 
switch 
49 
 
100% 
 
>12 
59.2% free of 
relapses   
NA 
 
Hospital Universitario 
Virgen Macarena, 
Seville222 
Spain Efficacy 47 
 
36.5% 
  
0.88 previous 24 
months  
3.89 R 16.3 
Multicenter1 Spain223 Spain FDO 148 9.1 
      
Reg 6.1 
Multicenter2 Spain224 Spain Registry 267 9.3 27% 
     
Reg 13.1 
Murcia225 Spain 
NTZ 
switch 
12 9.1 100% 
12 (with 
MP) 
31 0.3 
 
3.2 NA 15.4 
Murcia226 Spain FDO 18 7.5 
      
P 
 
Santiago de 
Compostela227 
Spain Efficacy 101 9.54 30% 
  
2.04 
  
R 
 
Valencia228 Spain 
NTZ 
switch 
11 6.8 100% 8 37.9 pre-NTZ 1.5 
 
3.5 P 11.7 
MS registry Sweden229 Sweden 
FTY vs 
NTZ 
628 (NTZ 447; 
NTZ-naïve 306) 
7.3 (NTZ 
4.5; NTZ-
naïve 6.4) 
48.1% 
    
2.63 (NTZ 
2.35; NTZ-
naïve 2.48) 
Reg >12 
Multicenter Sweden230 Sweden Registry 
674 (186 with 
12month FU)  
33% 
     
Reg 12 
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Cohort Country Focus Patients 
Time since 
diagnosis of 
MS (years) 
Patients with 
NTZ as 
previous 
treatment 
Washout 
period from 
NTZ (weeks) 
NTZ 
infusions 
Baseline ARR 
(previous 12 
months) 
Baseline 
MRI activity 
Baseline 
EDSS 
Source 
of data 
FU 
(months) 
Basel231 Switzerland 
NTZ 
switch 
15 11.8 100% 8 41.4 0.4 
100% free of 
T1Gd+ 
3.5 P* 8 
SWISSASCENT232 Switzerland PRO 212 6.6 28% 
  
0.8 
 
2.1 P 8.3 
Istanbul233 Turkey Efficacy 109 9.0 
   
1.9 
 
3.5 P 5.5 
Wimbledon234 UK FDO 143 
       
P* 
 
Boston235,236 USA Efficacy 177 11 15.3% 
  
0.5 
 
1.9 R >12 
Boston237 USA FDO 305 
       
R 
 
Cleveland Clinic238 USA FDO 317 12.1 11.6% 
     
R 3.3 
Cleveland Clinic239 USA Efficacy 306 
       
R* 11.1 
Cleveland Clinic240 USA Efficacy 196 11.5 
      
R 8.6 
Cleveland Clinic241 USA Other 232 10.5 
      
P 6.4 
Cleveland Clinic242 USA 
FTY vs 
DMF 
317 (DMF 426) 
14.1 (DMF 
12.3) 
12.4% (DMF 
11.7%)      
R 3 
Commercial health plan 
or Part D program243 
USA PRO 
        
R 
 
Cullman244 USA 
NTZ 
switch 
75 
 
100% 
     
NA >6 
Houston245 USA FDO 59 
       
R 
 
Medco Health 
Solutions246 
USA PRO 248 
       
R 12 
Multicenter1 USA247 USA PRO 205 
       
P 6 
Multicenter2 USA248 USA PRO 380 9.8 8.4% 
     
CS 
 
Multicenter3 USA249 USA NRO 
102 
Neurologists        
CS 
 
NARCOMS250 USA PRO 50 (NTZ 50) 
    
84% relapse free 
in previous 6 
month (FTY and 
NTZ) 
  
Reg 
54 (NTZ 
48) 
Partners MS Center251 USA 
FTY vs 
NTZ 
36 (NTZ 69) 
7.9 (8.4; p= 
0.71)    
0.92(NTZ 0.8; p= 
0.38) 
1.56 T1Gd+ 
in previous 
12 months 
(1.39; p= 
0.78) 
1.75 (NTZ 
1.5; p= 0.42) 
R 18 
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Cohort Country Focus Patients 
Time since 
diagnosis of 
MS (years) 
Patients with 
NTZ as 
previous 
treatment 
Washout 
period from 
NTZ (weeks) 
NTZ 
infusions 
Baseline ARR 
(previous 12 
months) 
Baseline 
MRI activity 
Baseline 
EDSS 
Source 
of data 
FU 
(months) 
PharMetrics Plus™252 USA PRO 
889 (GA 1233; 
IFN 1341; NTZ 
287) 
    
58.6% relapse 
free (GA 68.0%; 
IFN 68.2%; NTZ 
54.7%); ARR 0.67 
(GA 0.39; IFN 
0.39; NTZ 0.74) 
  
Claims 12 
PharMetrics Plus™253 USA 
FTY vs 
NTZ 
185 (NTZ 185) 
    
1.56 (NTZ 1.52) 
  
Claims 12 
PharMetrics Plus™254 USA 
FTY vs 
DMTs 
132 (GA 132) 
    
0.46; 66.7% 
relapse-free (GA 
0.49; 66.7%) 
  
Claims 12 
PharMetrics Plus™255 USA 
FTY vs 
DMTs 
128 (DMT 397) 
    
41.4% with >1 
relapse (DMTs 
15.1%; p< 
0.0001); ARR 1.7 
(DMTs 1.26) 
  
Claims 18 
Seattle256 USA Other 126 
       
R 7 
US LRx™ and 
PharMetrics Plus™257 
USA PRO 
1553 (DMF 
9363)        
Claims >6 
EPOC258 USA, Canada FDO 976 12.1 
   
0.8 
 
2.4 P 6 
EPOC259 USA, Canada PRO 847 
       
P 6 
EPOC260 USA, Canada PRO 790 (DMTs 263) 
12.1 (DMT 
11.7) 
0.1% (DMTs 
0%)   
0.8 (DMT 0.8) 
 
2.4 (DMT 
2.4) 
P 6 
EPOC261 USA, Canada PRO 790 (DMTs 263) 
12.1 (DMTs 
11.7)    
0.8 (DMT 8.8) 
 
2.4 (DMTs 
2.4) 
P 6 
EPOC262 USA, Canada Safety 783 (DMTs 245) 
       
P 6 
CS - Cross-Sectional; DMTs - Disease Modifying Treatments; EDSS - Expanded Disability Status Scale; FDO - First Dose Observation; FTY – Fingolimod; FU – Follow-up; MP – Methylprednisolone; MRI - Magnetic 
Resonance Imaging;   MS – Multiple Sclerosis;     NA - Non-available/unidentifiable;     NT – Non treated;     NTZ – Natalizumab;     P – Prospective;     P* - Presumably Prospective;     PRO - Patient Reported Outcomes;  
R – Retrospective; R* - Presumably Retrospective; Reg – Registry; T – Treated; T1Gd+ - T1 Gadolinium-Enhancing Lesions; WO - Washout 
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4.3.3. Relapse outcomes 
Relapse outcomes are summarized in Table 9. 
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Table 9. Relapse outcomes 
Cohort Focus Patients 
Time since 
diagnosis 
of MS 
(years) 
Patients 
with NTZ as 
previous 
treatment 
Washout 
period 
from NTZ 
(weeks) 
Baseline ARR 
(previous 12 
months) 
FU 
(months) 
Persistence 
[Adherence] 
ARR Relapses 
Relapse-
free 
REAL Registry 48 9.1 
   
8.5 
   
97.9% 
Multiple Sclerosis 
Treatment Registry 
FTY vs 
NTZ 
312 (NTZ 
1208) 
8.9 (NTZ 
7.8) 
54.2% 
 
1.8 (NTZ 2.3) 
21.5 (NTZ 
35.7) 
59% (NTZ 60%) 
Patients with 
>12 month FU 
0.4 (NTZ 0.35) 
77.8% ARR reduction 
 
Alsace 
NTZ 
switch 
59 
 
100% 6.8 
 
7 94.9% 
  
81.4% (WO 
> 12w 
50%; WO< 
12w 93%, 
p= 0.02)) 
Alsace Efficacy 290 
    
12 89.7% 0.17 
4.1 months to 1st relapse; 
70.5% ARR reduction 
82.4% 
Bordeaux FDO 24 
    
3 91.7% 
  
82.6% 
ENIGM 
NTZ 
switch 
333 
 
100% 
17 (55% 
patients 
without 
MP or 
other 
DMTs) 
 
6 97% 
  
80% 
Reims Efficacy 66 
    
11 (51.5% 
>12 
months) 
  
59.1% reduction vs baseline 68.3% 
Munich, Bochum, 
Marburg 
NTZ 
switch 
33 
 
100% 
 
0.2 (pre-NTZ 
2.5) 
20.3 
 
0.7 (if EDSS<3 
0.24; if EDSS> 
3 1.35) 
 
52% (if 
EDSS<3 
75%; if 
EDSS> 3 
18%) 
NeuroTransConcept 
FTY vs 
NTZ 
190 (NTZ 
239) 
9.89 (NTZ 
9.15)   
0.34 (NTZ 
0.42) 
12 
 
0.1 (NTZ 0.06) 70.6% ARR Reduction 
75.8% 
(NTZ 
71.3%) 
PANGAEA 
Large 
open 
trials 
3641 
(PEARL 
active 
457; 
PEARL 
inactive 
1248) 
8.2  (PEARL 
active 6.7; 
PEARL 
inactive 
7.3) 
18.4% 
31.9% 
Patients 
with WO 
<12 
1.5 (PNTZ 
0.9; PEARL 
active 1.23; 
PEARL 
inactive 
0.37) 
<24 
83.4%  (PEARL 
active 63.2%; PEARL 
inactive 85.9%); 
[Adherence 0.5 
days without MS 
medication within 2 
weeks (PEARL active 
1.6)] 
1st year 0.47; 
2nd year 0.34 
(PNTZ 1st year 
0.7; 2nd year 
0.34) (PEARL 
active 1st year 
1.2; 2nd year 
0.94) 
68.7% ARR reduction 64.08% 
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Cohort Focus Patients 
Time since 
diagnosis 
of MS 
(years) 
Patients 
with NTZ as 
previous 
treatment 
Washout 
period 
from NTZ 
(weeks) 
Baseline ARR 
(previous 12 
months) 
FU 
(months) 
Persistence 
[Adherence] 
ARR Relapses 
Relapse-
free 
Athens 
NTZ 
switch 
60 
 
33.3% 
  
>12 (MP 
8-12)    
93.3% 
(MPL 
88.9%) 
Ramat-Gann Efficacy 110 14.6 
   
20 
76.4% at 7.8 
months of 
treatment 
0.35 
  
Ferrara, Parma 
Modena, Reggio-
Emilia, Fidenza and 
Piacenza 
Efficacy 127 10.7 30.7% 18 1.2 10 
 
0.28 
Time to 1st relapse 148 days; 
76.7% ARR reduction 
69.3% 
(PNTZ 
patients 
59%) 
Gallarate 
NTZ 
switch 
32 
 
100% 15.6 
 
73.3% 
patients 
with >6 
months 
86.7% 
  
28.1% 
iMedWeb registry 
NTZ 
switch 
106 
(DMTs 
106) 
13.15 
(DMTs 
12.83) 
100% 
     
4.72% IR (DMTs 8.44; p= 0.02) 
 
L' Aquila, Pozzilli, 
Foggia 
Efficacy 142 
 
19.7% 
  
15 
   
90.8% 
(PNTZ 
82.1%) 
L' Aquila, Pozzilli, 
Foggia 
FTY vs 
NTZ 
100 (NTZ 
100)    
1.2 (NTZ 1.9) 12 
   
93% (NTZ 
87%) 
Milan 
NTZ 
switch 
61 
 
100% <52 
1.2 (0.15 on 
NTZ; 1.2 WO 
period) 
>6 
 
0.5 
  
Milan 
FTY vs 
NTZ 
37 (NTZ 
160) 
11.5 (NTZ 
10.1)   
1.2 (NTZ 1.3) >12 
At 24 month 81% 
(NTZ 58%) 
0.26  (NTZ 
0.04, p< 
0.001) 
72.9% ARR reduction; 
 
Orbassano 
NTZ 
switch 
35 (T 19; 
NT 24)   
>12 
     
68.6% (OT 
58.2%) 
Padua 
NTZ 
switch 
21 10.7 100% 12 
     
71.4% 
Multicenter Japan Registry 837 9.3 
  
0.98 
  
0.3 69.4% ARR reduction 
 
Tokyo Efficacy 44 13.1 0% 
   
75% 
  
95,5% 
Kuwait city Efficacy 76 7.82 2.6% 
 
13.2% 
relapse free 
18.5 94.7% 
  
77.6% 
MS registry Kuwait Efficacy 175 7.2 5.7% 
 
32.6% 
relapse free 
21.7 88.6% 
  
86.3% 
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Cohort Focus Patients 
Time since 
diagnosis 
of MS 
(years) 
Patients 
with NTZ as 
previous 
treatment 
Washout 
period 
from NTZ 
(weeks) 
Baseline ARR 
(previous 12 
months) 
FU 
(months) 
Persistence 
[Adherence] 
ARR Relapses 
Relapse-
free 
MSBase Registry 
NTZ 
switch 
89 12.8 100% 
95% with 
washout < 
4 months; 
2.6 months 
0.26 7.6 
 
0.38 (vs 0.26 
BL, p= 0.002; 
vs pre-NTZ 
1.54) 
 
79.8% 
MSBase Registry 
FTY vs 
NTZ 
171 (NTZ 
407) 
9.5 (NTZ 
9.4)   
1.29 (NTZ 
1.53) 
12 
 
0.36 (NTZ 
0.19) 
72.1% ARR reduction (NTZ 
87.6%)  
MSBase Registry 
FTY vs 
DMTs 
148 
(DMTs 
379) 
7.2 (DMTs 
7.3)   
1.3 (DMT 
1.2) 
11 
Persistence on FTY 
was better 
compared to DMT 
(hazard ratio 0.39) 
0.3 (DMTs 
0.45) 
76.9% ARR reduction (DMTs 
62.5%)  
Warsaw Efficacy 11 >3 
   
12 100% 
  
100% 
Coimbra 
NTZ 
switch 
29 10.4 100% 9.2 0.5 17.4 79.3% 
0.7 (p= 0.4 vs 
BL) 
69% with similar or improved 
ARR vs BL 
55.2% 
Moscow Efficacy 11 
        
82% 
Prešov 
NTZ 
switch 
9 
 
100% 3.3 
0 (pre-NTZ 
>2)     
44.4% 
Alicante 
NTZ 
switch 
8 11.1 100% 12 
pre-NTZ 
1.88; pre-FTY 
0.13; 
9.35 
 
0.8 
 
37% 
Hospital Ntra Sra 
Valme, Seville 
NTZ 
switch 
49 
 
100% 
 
59.2% free of 
relapses     
75.5% 
Hospital Universitario 
Virgen Macarena, 
Seville 
Efficacy 47 
 
36.5% 
 
0.88 
previous 24 
months 
16.3 
 
0.25 (PNTZ 
patients 0.49) 
71.6% ARR reduction (PNTZ 
44.3%)  
Multicenter2 Spain Registry 267 9.3 27% 
  
13.1 96.6% 
  
80% 
Murcia 
NTZ 
switch 
12 9.1 100% 
12 (with 
MP) 
0.3 15.4 
   
86.4% 
Santiago de 
Compostela 
Efficacy 101 9.54 30% 
 
2.04 
 
96% 2.14 
  
Valencia 
NTZ 
switch 
11 6.8 100% 8 pre-NTZ 1.5 11.7 90.9% 0.09 
9.1% patients with 1 mild 
relapse 
90.9% 
Basel 
NTZ 
switch 
15 11.8 100% 8 0.4 8 86.7% 
  
46% 
SWISSASCENT PRO 212 6.6 28% 
 
0.8 8.3 96% 0.2 75% ARR Reduction 88% 
Istanbul Efficacy 109 9.0 
  
1.9 5.5 94.5% 
  
90% 
Boston Efficacy 177 11 15.3% 
 
0.5 >12 
   
83.6% 
Cleveland Clinic Efficacy 306 
    
11.1 76.1% 0.12 
 
64% 
Cleveland Clinic 
FTY vs 
DMF 
317 (DMF 
426) 
14.1 (DMF 
12.3) 
12.4% (DMF 
11.7%)   
3 92% (DMF 82%) 
 
0.03 relapses/patient (DMF 
0.12) 
97% (DMF 
89%) 
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Cohort Focus Patients 
Time since 
diagnosis 
of MS 
(years) 
Patients 
with NTZ as 
previous 
treatment 
Washout 
period 
from NTZ 
(weeks) 
Baseline ARR 
(previous 12 
months) 
FU 
(months) 
Persistence 
[Adherence] 
ARR Relapses 
Relapse-
free 
Partners MS Center 
FTY vs 
NTZ 
36 (NTZ 
69) 
7.9 (8.4; p= 
0.71)   
0.92(NTZ 0.8; 
p= 0.38) 
18 77.8% (NTZ 63.8%) 
 
patients treated with NTZ had 
a longer time to relapse (2.20  
p = 0.095) in the unadjusted 
analysis; patients treated with 
NTZ had a significantly lower 
hazard of a relapse in each 
model; 
 
PharMetrics Plus™ 
FTY vs 
NTZ 
185 (NTZ 
185)    
1.56 (NTZ 
1.52) 
12 
71.9% (NTZ 76.2%; 
p=0.3427)   
68.1% 
(NTZ 
68.6%; p= 
0.9110) 
PharMetrics Plus™ 
FTY vs 
DMTs 
132 (GA 
132)    
0.46; 66.7% 
relapse-free 
(GA 0.49; 
66.7%) 
12 
73.5% (GA 62.9%; 
p= 0.0643) 
0.19 (GA 0.51) 
59% reduction in the 
probability of having a relapse 
vs GA (p =0.0091); 360 days 
median time to 1st relapse 
(GA 274); Patients treated 
with FTY had 62% fewer 
relapses per year (p =0.0013) 
87.1% (GA 
75%; p= 
0.012) 
PharMetrics Plus™ 
FTY vs 
DMTs 
128 (DMT 
397)    
41.4% with 
>1 relapse 
(DMTs 
15.1%; p< 
0.0001); ARR 
1.7 (DMTs 
1.26) 
18 
57.0% (DMTs 
45.1%; p=0.0187) 
0.32 (DMTs 
0.64; p= 
0.0006) 
52% reduction in the 
probability of having a relapse 
in the post-index persistence 
period compared with IFN/GA 
(p=0.0097); 50% fewer 
relapses per year during the 
persistence period than those 
treated with IFN or GA 
(p=0.0006) 
68.7% 
ARR – Annualized Relapse Rate; BL – Baseline; DMTs - Disease Modifying Treatments; EDSS - Expanded Disability Status Scale; FTY – Fingolimod; FU – Follow-up; GA – Glatiramer Acetate; MP – Methylprednisolone; 
MRI - Magnetic Resonance Imaging;   MS – Multiple Sclerosis;    NT – Non treated;     NTZ – Natalizumab; T – Treated; w – weeks;  
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4.3.4. Disability outcomes 
Disability outcomes are summarized in Table 10. 
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0 Table 10. Disability outcomes 
Cohort Focus Patients 
Time since 
diagnosis of MS 
(years) 
Patients with 
NTZ as previous 
treatment 
Washout 
period from 
NTZ (weeks) 
Baseline ARR 
(previous 12 
months) 
Baseline EDSS 
FU 
(months) 
Baseline EDSS EDDS difference 
Multiple Sclerosis 
Treatment Registry 
FTY vs 
NTZ 
312 (NTZ 1208) 8.9 (NTZ 7.8) 54.2% 
 
1.8 (NTZ 2.3) 2.6 (NTZ 3.2) 
21.5 (NTZ 
35.7) 
2.6 (NTZ 3.2) 
 
Alsace Efficacy 290 
    
3.6 12 3.6 0.1 
Munich, Bochum, 
Marburg 
NTZ 
switch 
33 
 
100% 
 
0.2 (pre-NTZ 2.5) 
3.2 (pre-NTZ 
3.1) 
20.3 
3.2 (pre-NTZ 
3.1) 
0.1 
NeuroTransConcept 
FTY vs 
NTZ 
190 (NTZ 239) 9.89 (NTZ 9.15) 
  
0.34 (NTZ 0.42) 2.3 (NTZ 3.3) 12 2.3 (NTZ 3.3) -0.14 (NTZ -0.13) 
PANGAEA 
Large 
open 
trials 
3641 (PEARL 
active 457; 
PEARL inactive 
1248) 
8.2  (PEARL 
active 6.7; 
PEARL inactive 
7.3) 
18.4% 
31.9% 
Patients with 
WO <12 
1.5 (PNTZ 0.9; 
PEARL active 1.23; 
PEARL inactive 
0.37) 
3 (PEARL active 
2.60; PEARL 
inactive 2.20) 
<24 
3 (PEARL active 
2.60; PEARL 
inactive 2.20) 
-0.07 (PEARL 
active 0.5) 
Tel-Aviv Other 30 
   
1.2 
0.4 increase in 
previous 12 
months 
12 
0.4 increase in 
previous 12 
months 
0 
Ferrara, Parma 
Modena, Reggio-Emilia, 
Fidenza and Piacenza 
Efficacy 127 10.7 30.7% 18 1.2 
3.1 (PNTZ 
patients 3.6) 
10 
3.1 (PNTZ 
patients 3.6) 
0 (PNTZ patients 
0.1, p= 0.14) 
L' Aquila, Pozzilli, Foggia Efficacy 142 
 
19.7% 
   
15 
  
L' Aquila, Pozzilli, Foggia 
FTY vs 
NTZ 
100 (NTZ 100) 
   
1.2 (NTZ 1.9) 2.6 (NTZ 2.9) 12 2.6 (NTZ 2.9) 
 
Milan 
FTY vs 
NTZ 
37 (NTZ 160) 11.5 (NTZ 10.1) 
  
1.2 (NTZ 1.3) 2.1 (NTZ 2.5) >12 2.1 (NTZ 2.5) 0 (NTZ 0) 
Orbassano 
NTZ 
switch 
35 (T 19; NT 24) 
  
>12 
    
0.2 (OT 0.5; p NS) 
Kuwait city Efficacy 76 7.82 2.6% 
 
13.2% relapse free 2.93 18.5 2.93 -0.98 (p< 0.0001) 
MS registry Kuwait Efficacy 175 7.2 5.7% 
 
32.6% relapse free 2.6 21.7 2.6 -0.34 (p= 0.03) 
MSBase Registry 
FTY vs 
NTZ 
171 (NTZ 407) 9.5 (NTZ 9. 4) 
  
1.29 (NTZ 1.53) 3 (NTZ 3.5) 12 3 (NTZ 3.5) 
area under 
disability-time 
curve 0.04 (NTZ -
0.12) 
MSBase Registry 
FTY vs 
DMTs 
148 (DMTs 379) 7.2 (DMTs 7.3) 
  
1.3 (DMT 1.2) 2.5 (DMT 2.5) 11 2.5 (DMTs 2.5) 
no difference in 
the post-switch 
disability 
between the two 
groups 
Warsaw Efficacy 11 >3 
    
12 
  
Coimbra 
NTZ 
switch 
29 10.4 100% 9.2 0.5 2.7 17.4 2.7 0.1 (p= 0.6 vs BL) 
Alicante 
NTZ 
switch 
8 11.1 100% 12 
pre-NTZ 1.6; pre-
FTY 0.13; 
2.4 9.35 2.4 1.0 
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Cohort Focus Patients 
Time since 
diagnosis of MS 
(years) 
Patients with 
NTZ as previous 
treatment 
Washout 
period from 
NTZ (weeks) 
Baseline ARR 
(previous 12 
months) 
Baseline EDSS 
FU 
(months) 
Baseline EDSS EDDS difference 
Hospital Ntra Sra Valme, 
Seville 
NTZ 
switch 
49 
 
100% 
 
59.2% free of 
relapses     
Hospital Universitario 
Virgen Macarena, Seville 
Efficacy 47 
 
36.5% 
 
0.88 previous 24 
months 
3.89 16.3 3.89 0.04 
Multicenter2 Spain Registry 267 9.3 27% 
   
13.1 
  
Murcia 
NTZ 
switch 
12 9.1 100% 12 (with MP) 0.3 3.2 15.4 3.2 0 
Santiago de Compostela Efficacy 101 9.54 30% 
 
2.04 
    
Valencia 
NTZ 
switch 
11 6.8 100% 8 pre-NTZ 1.5 3.5 11.7 3.5 -0.3 
Multicenter Sweden Registry 
674 (186 with 
12month FU)  
33% 
   
12 
 
0 
Boston Efficacy 177 11 15.3% 
 
0.5 1.9 >12 
  
BL – Baseline;   DMTs - Disease Modifying Treatments;   EDSS - Expanded Disability Status Scale;    FTY – Fingolimod;     FU – Follow-up;   GA – Glatiramer Acetate; MP – Methylprednisolone; MS – Multiple Sclerosis;    
NS – Non Significative; NT – Non treated;     NTZ – Natalizumab; OT – Other Treatments; PNTZ- Patients Previously Treated with NTZ; T – Treated;  
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4.3.5. MRI outcomes 
MRI outcomes are summarized in Table 11. 
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Table 11. MRI outcomes 
Cohort Focus Patients 
Time since 
diagnosis of 
MS (years) 
Patients with 
NTZ as previous 
treatment 
Washout 
period from 
NTZ (weeks) 
Baseline MRI 
activity 
FU (months) 
Persistence 
[Adherence] 
MRI activity free MRI 
Reims Efficacy 66 
    
11 (51.5% >12 
months)  
T2 84.8% 
 
Ferrara, Parma 
Modena, Reggio-
Emilia, Fidenza 
and Piacenza 
Efficacy 127 10.7 30.7% 18 
65,4% (31.5% 
T1Gd+) 
10 
 
54.9%; T1Gd+ 
83.1%; (PNTZ 
45.8%; T1Gd+ 
66.7%); 
 
Gallarate Other 55 12.5 21.8% 
  
12 
 
69.1% 
 
Gallarate 
NTZ 
switch 
32 
 
100% 15.6 
 
73.3% 
patients with 
>6 months 
86.7% 96.7% 
 
L' Aquila, Pozzilli, 
Foggia 
Efficacy 142 
 
19.7% 
  
15 
 
82.8% 
 
L' Aquila, Pozzilli, 
Foggia 
FTY vs 
NTZ 
100 (NTZ 
100)    
78% of patients 
(NTZ 90%) 
12 
 
75% (NTZ 93%) 
 
Padua 
NTZ 
switch 
21 10.7 100% 12 
   
52.4% 
 
Kuwait city Efficacy 76 7.82 2.6% 
 
22.4% MRI 
activity free 
18.5 94.7% 82.9% 
 
MS registry 
Kuwait 
Efficacy 175 7.2 5.7% 
 
23.3% MRI 
activity free 
21.7 88.6% 81.7% 
 
Guaynabo Efficacy 50 
    
12 
  
86% free of new black holes; 
90% free of Brain Volume 
Loss; 2% with Brain volume 
loss and black hole; 
Hospital Ntra Sra 
Valme, Seville 
NTZ 
switch 
49 
 
100% 
    
44.9% 
 
Murcia 
NTZ 
switch 
12 9.1 100% 12 (with MP) 
 
15.4 
 
T1Gd+ 100% 
 
Valencia 
NTZ 
switch 
11 6.8 100% 8 
 
11.7 90.9% T1Gd+ 81.8% 
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Basel 
NTZ 
switch 
15 11.8 100% 8 
100% free of 
T1Gd+ 
8 86.7% 46.2% 
 
Boston Efficacy 177 11 15.3% 
  
>12 
 
85.9% 
 
Cleveland Clinic 
FTY vs 
DMF 
317 
(DMF 
426) 
14.1 (DMF 
12.3) 
12.4% (DMF 
11.7%)   
3 
92% (DMF 
82%) 
T1Gd+ 95% (DMF 
94%)  
Partners MS 
Center 
FTY vs 
NTZ 
36 (NTZ 
69) 
7.9 (8.4; p= 
0.71)   
1.56 T1Gd+ in 
previous 12 
months (1.39; p= 
0.78) 
18 
77.8% (NTZ 
63.8%)   
DMF – Dimethyl Fumarate; DMTs - Disease Modifying Treatments;    FTY – Fingolimod;     MP – Methylprednisolone; NTZ – Natalizumab; PNTZ- Patients Previously Treated with NTZ; T1Gd+ - T1 Gadolinium-Enhancing 
Lesions; T2 - T2-weighted lesions 
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4.3.6. Composed outcomes 
Composed outcomes are summarized in Table 12. 
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5
6 Table 12. Composed outcomes 
Cohort Focus Patients 
Time since 
diagnosis of 
MS (years) 
Patients with 
NTZ as 
previous 
treatment 
Washout 
period from 
NTZ (weeks) 
Baseline 
ARR 
(previous 12 
months) 
FU 
(months) 
Free of relapse 
and EDSS 
progression 
Free of 
relapse 
and 
T1Gd+ 
Free of 
relapse 
and MRI 
activity 
Free of EDDS 
progression 
and MRI 
activity 
Free of relapse, 
EDDS 
progression and 
MRI activity 
Reims Efficacy 66 
    
11 (51.5% 
>12 
months) 
 
89.1% 
   
NeuroTransConcept 
FTY vs 
NTZ 
190 
(NTZ 
239) 
9.89 (NTZ 
9.15)   
0.34 (NTZ 
0.42) 
12 
71.1% (NTZ 
62.0%)     
Gallarate Other 55 12.5 21.8% 
 
1.7 in 
previous 24 
months 
12 67.3% 
    
Gallarate 
NTZ 
switch 
32 
 
100% 15.6 
 
73.3% 
patients 
with >6 
months 
70% 
    
L' Aquila, Pozzilli, 
Foggia 
Efficacy 142 
 
19.7% 
  
15 79.7% 
   
72.5% 
L' Aquila, Pozzilli, 
Foggia 
FTY vs 
NTZ 
100 
(NTZ 
100) 
   
1.2 (NTZ 1.9) 12 
    
70% (NTZ 79%) 
Milan 
FTY vs 
NTZ 
37 (NTZ 
160) 
11.5 (NTZ 
10.1)   
1.2 (NTZ 1.3) >12 
68% (NT> 92%, 
p= 0.0003)   
42% (NT> 93%, 
p= 0.0003)  
Padua 
NTZ 
switch 
21 10.7 100% 12 
    
47.6% 
  
Hospital Universitario 
Virgen Macarena, 
Seville 
Efficacy 47 
 
36.5% 
 
0.88 
previous 24 
months 
16.3 63.8% 
    
Multicenter2 Spain Registry 267 9.3 27% 
  
13.1 56.3% 
    
Boston Efficacy 177 11 15.3% 
 
0.5 >12 
  
87.6% 
 
50.3% 
Cleveland Clinic Efficacy 306 
    
11.1 
  
59.3% 
  
Cullman 
NTZ 
switch 
75 
 
100% 
  
>6 
 
97.3% 
   
ARR – Annualized Relapse Rate; EDSS - Expanded Disability Status Scale; FTY – Fingolimod; FU – Follow-up; MRI - Magnetic Resonance Imaging; NT – Non treated; NTZ – Natalizumab; T1Gd+ - T1 Gadolinium-
Enhancing Lesions;  
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4.3.7. PRO, FDO and Other outcomes 
PRO, FDO and Other outcomes are summarized in Table 13. 
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8 Table 13. PRO, FDO and Other outcomes 
Cohort Patients 
Patients 
with NTZ as 
previous 
treatment 
FU 
(months) 
Persistence 
[Adherence] 
PRO/Other 
Neurologists 
Reported Outcomes 
FDO 
São Paulo 180 
     
Pre-FTY (2.8% high blood pressure;  2.2% right or 
left branch block; 1.1% sinus tachycardia; 1.1% 
sinus bradycardia); 89.4% discharged at 6h; 1.7% 
ICU 
Gilenya* Go 
Program(TM) 
1700 
  
85.5% 
  
0.29% AV block; 0.17% bradycardia;  99.3% 
continued on treatment post-FDO; 
Multiple 
Sclerosis 
Registry 
496 32.3% > 3 89.2% 
  
3.9% required prolonged cardiac monitoring 
(2.2% bradycardia; 2.7% 2nd degree grade AVB 
type I; 0.5% patient sinus arrest); 2.3% 
respiratory complaints, mostly dyspnoea; 
Bordeaux 24 
 
3 91.7% 
  
8.3% symptomatic bradycardia; 4.2% treatment 
discontinuation after FDO 
GRACE 198 
   
HADS 8.1 (baseline 8.8) (p=0.001) 
  
Dresden 36 
     
9.5% maximum decrease of heart rate between 
3rd and 5th hour after FTY first dose 
PANGAEA 
3641 (PEARL 
active 457; 
PEARL inactive 
1248) 
18.4% <24 
83.4%  (PEARL 
active 63.2%; PEARL 
inactive 85.9%); 
[Adherence 0.5 days 
without MS 
medication within 2 
weeks (PEARL active 
1.6)] 
>96.9% of patients rated FTY tolerability as 
good or very good; >89.5% of patients and 
physicians rated FTY effectiveness as good or 
very good. 89.5% stabilized or better QoL 
(Eq5D) 
>94.1% physicians 
rated FTY 
tolerability as good 
or very good; 
>90.7% physicians 
rated FTY 
effectiveness as 
good or very good. 
1.7% cardiac AEs (0.03% 1st degree AVB; 0.3% 
2nd degree AVB; 0.3% bradycardia;  0.45% lowest 
HR at 6h; 0.03% QTc interval ≥ 500 msec; 0.7% 
other clinical findings); 0.77% prolonged 
monitoring; 
START 1640 
     
91.2% discharged after 6h; 1% required overnight 
monitoring; 12bpm average maximum decrease 
of heart rate; 4bpm average decrease of heart 
rate 6h after FTY first dose; nadir HR at 4.1; 99% 
with heart rate >45bpm at any time;  Within the 
first 6 hours the HR returned to 93 % of the 
baseline level; 3.6% with de novo 1st degree AVB; 
1.6% 2nd degree or higher AVB; 
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Cohort Patients 
Patients 
with NTZ as 
previous 
treatment 
FU 
(months) 
Persistence 
[Adherence] 
PRO/Other 
Neurologists 
Reported Outcomes 
FDO 
Tel-Aviv 30 
 
12 
 
FTY treatment demonstrated preservation of 
structural thickness over one year of treatment. 
A numerical increase has been observed in all 
but one cognitive measure. The lack of 
statistical significance may be due to the very 
small sample. FTY treatment demonstrated 
preservation of structural thickness over one 
year of treatment. no difference in EDSS vs BL. 
  
Gallarate 55 21.8% 12 
 
Active patients had more relapses before FTY 
(1.8 Vs 1.5, p = 0.043), a lower mean white 
blood cell count (5043.9/mm3 Vs 5328.8/ mm3, 
p = 0.027) and a lower mean lymphocyte count 
(653.8/mm3 Vs 756.8/mm3 , p = 0.05) 
compared to disease-free patients 
  
Milan 37 (NTZ 160) 
 
>12 
At 24 month 81% 
(NTZ 58%) 
26% patients improved in cognitive tests (NTZ 
7%)   
Multicentre 
Italy 
906 24.3% 3.14 96% 
  
95.3% patients with uneventful FDO; 1.3% 
bradycardia; 0.1% 1st degree AVB; 0.2% 2nd 
degree AVB; 0.1% palpitations; 0.1% sinus 
arrhythmia; 0.1% ventricular premature beats; 
95.7% discharged after 6h; 
Naples 112 
     
20.5% with ECG abnormalities pre-FTY; 75.4 bpm 
pre-FTY; -6.3 bpm at 5h; -4.6 bpm at 5h; 5ms PR 
interval increase; 0.5ms QTc decrease; 0.9% 
symptomatic bradycardia (with headache and 
lower limbs weakness); 1.8% 2nd degree AVB; 
16.4% sinus bradycardia, 9.1% right bundle 
branch block, 9.1% ventricular extrasystole, 3.6% 
1st degree AV block; 
Rome 55 
     
-14.8% HR at nadir; nadir at 4h; 5.5% 1st degree 
AVB; 1.8% 2nd degree AVB; 
Turin 35 
 
6 
 
2.9% de novo headache; 
  
Multicentre 
Japan 
837 
     
3.1% bradycardia, 1.4% HR decreased, 0.9% 2nd 
degree AVB; 
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Cohort Patients 
Patients 
with NTZ as 
previous 
treatment 
FU 
(months) 
Persistence 
[Adherence] 
PRO/Other 
Neurologists 
Reported Outcomes 
FDO 
FIRST 2417 10.5% 4 94.4% 
  
96.7% discharged at 6h; 1.3% HR< 45bpm; 0.6% 
Palpitations; 0.6% Bradycardia; 0.1% Tachycardia; 
0.1% Cardiovascular disorder; 0.1% Angina 
pectoris; 0.2% 2nd degree AVB; 0.2% Ventricular 
extra systoles; 0.04% Ventricular 
tachycardia;0.04% Cardiac disorder;0.04% Sinus 
bradycardia; 0.04% AVB 
PASSAGE 1596 19.6% 9 
   
3.5% bradyarrhythmia (1.3% bradycardia; 0.3% 
1st degree AVB; 0.1% 2nd degree AVB) 
Guaynabo 25 
 
6 
   
no significant CV events; 100% discharged after 
6H; 
Granada 42 
  
98% 
  
95.2% asymptomatic bradycardia; 11.9% required 
prolonged monitoring after the 6h; 
Multicenter1 
Spain 
148 
 
6.1 100% 
  
9.5% average decrease of heart rate 6h after FTY 
first dose; 1.2mmHg decrease in systolic BP; 
3.5mmHg decrease in diastolic BP; 
Multicenter2 
Spain 
267 27% 13.1 96.6% 
  
88.4% discharged at 6h; mean monitoring time 
7.3 hours; 
Murcia 18 
     
5.56% symptomatic bradycardia; asymptomatic 
ECG changes were observed at 6 (44%) and 24 
hours (20%) after first dose of FTY; no clinical or 
ECG effects requiring FTY discontinuation. 
Multicentre 
Sweden 
674 (186 with 
12month FU) 
33% 12 89.6% 
-12.2% MSSS; +8.7% SDMT; -7.4% MSIS-29 
physical score; -13.3% MSIS-29 psychological 
score; +6.3% EQ-5D 
 
0.59% cardiac disorders (bradycardia, AV-block, 
hypertension); 
SWISSASCENT 212 28% 8.3 96% 
QoL remained stable over time in patients 
switching from other DMTs but those patients 
showed a significant improvement in the 
mental subscore; Treatment satisfaction 
improved 14 points upon switch from other 
DMTs to FTY (p= 0.001). This was true for all 
domains of the TSQM-9 scale. 
 
99.5% patients did not require any medical 
intervention, nor monitoring on day two (98%), 
and continued FTY treatment after the FDO 
(99.5%) 
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Cohort Patients 
Patients 
with NTZ as 
previous 
treatment 
FU 
(months) 
Persistence 
[Adherence] 
PRO/Other 
Neurologists 
Reported Outcomes 
FDO 
Istanbul 109 
 
5.5 94.5% 
   
Wimbledon 143 
  
99.4% 
   
Boston 305 
  
84.59% 
  
-14 bpm at nadir; 98.7% uneventful; 0.66% 2nd 
degree AVB; 
Cleveland 
Clinic 
317 11.6% 3.3 90.5% 
There were no significant differences in T25FW, 
PHQ-9, MSPS or EQ5D (n=164) compared to 
baseline. 
 
Uneventful in 97.8%; 0.9% symptomatic 
bradycardia; 0.6% Chest tightness; 0.3% 
Hypertension; 0.3% Sensory symptoms; −11.5 
bpm at 3 h; −12.0 bpm at 6 h; −1.8 mmHg Systolic 
BP  at 3h and at 6 h; −3.3 mmHg Diastolic blood 
pressure at 3 h and −3.7 mmHg at 6h; 
Cleveland 
Clinic 
306 
 
11.1 76.1% 
MS performance scale, PHQ9, and EQ5D 
remained stable at 12 month 
follow-up (p>0.2 for all). T25FW was 
significantly slower at 12 months 
compared with BL (difference=1.16 seconds, 
paired t-test p = 0.013). 
  
Cleveland 
Clinic 
196 
 
8.6 
 
85% stable or improved in T25FW; 91.6% stable 
or improved in 9PHT; -0.03 mean change in 
PHQ9 (p= 0.06); -0.005  mean change in EQ-5D 
(p= 0.02);  0.54 mean change in MSPS (p= 0.20); 
Clinician-derived 
and patient-
reported disability 
scores and patient-
reported QoL 
measures were 
stable 
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Cohort Patients 
Patients 
with NTZ as 
previous 
treatment 
FU 
(months) 
Persistence 
[Adherence] 
PRO/Other 
Neurologists 
Reported Outcomes 
FDO 
Cleveland 
Clinic 
232 
 
6.4 
 
Mean GCIP thickness at BL was 70.64mum, with 
mean change of -0.37mum (p = 0.0038). Mean 
macular RNFL thickness at BL was 27.95mum 
with mean change of 0.12mum (p = 0.1456). 
The mean outer retina thickness at BL was 
125.8mum, with mean change of 0.406mum (p 
= 0.0355), and the mean peripapillary RNFL 
thickness was 81.8mum with mean change of -
0.97mum (p = 0.0053). 
  
Houston 59 
     
5% rhythm disturbances (3% bradycardia 
secondary to atrioventricular conduction 
abnormality; 1.7% sinus bradycardia with 
accelerated idioventricular rhythm.) 
Multicenter1 
USA 
205 
 
6 
 
TSQM improvement 17.57 vs 2.10 (IM IFN a), 
24.7 vs 2.29 (SC IFN a) and 22.34 vs 4.45; TSQM 
subscale scores: Effectiveness, 13.31 vs 1.37 (IM 
IFN a), 15.07 vs 1.62 (SC IFN a), 17.59 vs 0.68 
(IFN b); Side Effects, 30.62 vs 6.56 (IM IFN a), 
27.83 vs -0.42 (SC IFN a), 21.50 vs -1.24 (IFN b); 
Convenience, 43.83 vs 5.70 (IM IFN a), 42.36 vs 
1.66 (SC IFN a), 41.57 vs 1.31; FSS 
improvement: -0.33 vs -0.07 (IM IFN a), -0.44 vs 
0.15 (SC IFN a), -0.46 vs 0.08 (IFN b). BDI-II 
improvement -3.21 vs -2.26 (IM IFN a), -2.73 vs 
-0.10 (SC IFN a), -4.16 vs 0.14 (IFN b); CGI-I 
improvement 3.25 vs 4.06 (IM IFN a), 3.11 vs 
3.98 (SC IFN a) and 3.35 vs 3.97 (IFN b) 
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Cohort Patients 
Patients 
with NTZ as 
previous 
treatment 
FU 
(months) 
Persistence 
[Adherence] 
PRO/Other 
Neurologist 
Reported Outcomes 
FDO 
Multicenter2 
USA 
380 8.4% 
  
80% reported their first dose of FTY was 
moderately, very, or extremely manageable, 
convenient, and easy to take; 80% reported 
experiencing a side effect; 42.4% reported the 
side effect was “not at all” or only “a little” 
difficult to tolerate; 2.9% reported a “not at all 
satisfied” first-dose experience; TSQM scale 
scores (79.4  side effect,  71.7  convenience, 
70.1 effectiveness, 68.9 global satisfaction); 
  
Multicenter3 
USA 
102 
Neurologists    
85.3% with >1 FTY patient; 5.2% of patients 
under FTY treatment; 94% reported that 
"All/Most” of their patients were highly 
adherent with FTY; 31% reported that their 
patients were “Very Satisfied” or “Extremely 
Satisfied” with FTY; 
  
NARCOMS 50 (NTZ 50) 
 
54 (NTZ 
48)  
0.5 increase in PDSS (NTZ 0.1; p=0.02) 
  
Seattle 126 
 
7 
 
Trend of RNFL and GC-IP thinning was noted 
but did not reach statistical significance. The 
observed trend in macular volume change was 
independent of age, gender, time since MS 
diagnosis, or prior history of optic neuritis. 
  
EPOC 976 
 
6 
   
8.1 maximum HR decrease (at 5h); 7.2 average 
decrease of heart rate 6h after FTY first dose; 
0.01% with HR< 40bpm; 18.2% with new ECG 
abnormalities (8.8% 1st degree AVB; 7.2% sinus 
bradycardia; 0.6% Left anterior hemiblock; 1.7% 
Atrial premature complex; 0.6% Biphasic 
Twaves); 98.5% discharged at 6h; 1.3% Required 
extended observation after 6h on day 1; 0.5% 
Required extended observation on day 2; 
1.3mmHg decrease in systolic BP; 3.1mmHg 
decrease in diastolic BP; 1.2% Symptomatic 
bradycardia 
EPOC 847 
 
6 
 
50.5% recovered from depression (DMT 25.3%); 
8.1% became depressed (DMT 9.3%);   
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Cohort Patients 
Patients 
with NTZ as 
previous 
treatment 
FU 
(months) 
Persistence 
[Adherence] 
PRO/Other 
Neurologists 
Reported Outcomes 
FDO 
EPOC 
790 (DMTs 
263) 
0.1% (DMTs 
0%) 
6 
90.4% (DMTs 
87.1%) 
TQSM scores were significantly greater with FTY 
than with DMT (Global satisfaction, 
Effectiveness, Side Effects, and Convenience; p< 
0.0001); Improvements in FSS and BDI-II score 
were  significantly greater with FTY than with 
DMT (p< 0.0001); PRIMUS Activities score were 
numerically  reduced (better outcomes in 
fatigue and depression) with FTY versus DMT; 
SF-36 scores were significantly greater with FTY 
than with DMT (p< 0.0001), except for the 
domains ‘Physical functioning’ and ‘General 
health perceptions’ 
  
EPOC 
790 (DMTs 
263)  
6 
 
BDI-II; Somatic subdomain, 7.5 (at BL) to 5.4 (at 
Month 6) (DMTs 6.9 to 6.7) (p<0.0001); 
Affective subdomain, 4.2 (at BL) to 2.9 (at 
Month 6)(DMTs 4.0 to 3.8) (p=0.0001) 
  
AEs – Adverse Events; AV – Atrioventricular; AVB – AV Block;    BDI-II - Beck Depression Inventory-II;     BL – Baseline;    Bpm – beats per minute;    DMTs - Disease Modifying Treatments;   ECG – Electrocardiogram; 
EDSS - Expanded Disability Status Scale;    FDO – First Dose Observation;    FTY – Fingolimod;  FU – Follow-up;    GCIP - Ganglion Cell/Inner Plexiform;   HADS - Hospital Anxiety and Depression Scale;   HR – Heart Rate; 
IFN – Interferon;    IM – Intramuscular;   MSIS - Multiple Sclerosis Impact Scale;   MSPS - Multiple Sclerosis Performance Scales;   MSSS - Multiple Sclerosis Severity Score; PDSS - Patient Determined Disease Steps; 
PHQ-9 - Patient Health Questionnaire 9; PRO - Patient Reported Outcomes; QoL - Quality of Life; RNFL - Retinal Nerve Fibre Layer; SC – Subcutaneous; SDMT - Symbol Digit Modalities Test; T25FW - Timed 25-Foot 
Walk; TSQM - Treatment Satisfaction Questionnaire for Medication 
  
65 
 
4.3.8. Safety outcomes 
Analysing real world evidence for safety outcomes is somehow tricky, because most of 
the studies have less than 500 patients, and thus incidence rate of rare events can be 
unrealistically overestimated. A cut-off of 500 patients in each study was used to avoid this 
artefact. This resulted in a substantial drop of the number of studies available to review. 
The results can be found on Table 14 where in the last columns are the results of the 
pooled analysis of the phase III trials, and the pooled analysis of only FREEDOMS, FREEDOMS 
II and TRANSFORMS, to be used as reference. 
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6
6 Table 14. Safety outcomes 
 
Cohort 
EPOC260,262 FIRST208 
Gilenya* Go 
Program(TM)
172 
LONGTERMS209,
210 
Multicentre 
Sweden230 
Multicentre 
Japan204 
PASSAGE214 
Phase III 
studies44 
FREEDOMS
38 
TRANSFORMS
48 
Comment 
   
Incidence per 
100 patient-
years 
   
9,070 
patient-
years 
  
Patients 783 2417 1700 1655 674 809 1419 1640 425 429 
Any AE 78.8% 
  
296.7 3.1% 40.9% 33.6% 95.8% 94,4% 86,0% 
AEs leading to study drug discontinuation 5.2% 
   
5.9% 11.4% 1.27% 7.6% 7,5% 5,6% 
AEs leading to study drug discontinuation after 
1st dose   
0.6% 
       
Abnormal laboratory value leading to study drug 
       
4.8% 
  
Any SAEs 4.0% 
   
1.93% 17.2% 4.2% 11.9% 10,1% 7,0% 
           
Infections 
   
68.3 
  
9.3% 74.5% 
  
Infections and infestations 30.1% 
   
0.44% 
     
Infections in patient-years 
       
114.7 
  
Any serious infection 
       
2.9% 
  
Any severe infection 
       
5.2% 
  
Appendicitis (SAE) 
       
0.3% 
  
Herpes infection (SAE) 
       
0.4% 
 
0,2% 
Any Herpes infection 
       
11.2% 8,7% 2,1% 
Herpes Zoster 
     
1.2% 0.8% 3.0% 
  
Herpes Zoster (SAE) 
     
0.9% 
 
0.1% 
  
Influenza 
   
4.4 
   
12.8% 12,9% 6,8% 
Lower respiratory tract and lung infection 
       
13.2% 9,6% 
 
Bronchitis 1.5% 
  
3.5 
   
9.2% 8,0% 
 
Pneumonia 
        
0,9% 
 
Upper respiratory tract infection 6.5% 
  
6.2 
 
0.7% 0.8% 19.1% 49,9% 7,2% 
Nasopharyngitis 5.5% 
  
11.9 
 
0.6% 1.3% 30.4% 27,1% 20,5% 
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Cohort 
EPOC260,262 FIRST208 
Gilenya* Go 
Program(TM)
172 
LONGTERMS209,
210 
Multicentre 
Sweden230 
Multicentre 
Japan204 
PASSAGE214 
Phase III 
studies44 
FREEDOMS
38 
TRANSFORMS
48 
Sinusitis 3.3% 
  
3.3 
    
6,6% 
 
Rhinitis 
        
5,9% 
 
Pharyngitis 
        
6,4% 
 
Reactivation of chronic viral infections 
   
5.3 
      
Urinary tract infection 5.1% 
  
4.3 
  
1.5% 12.1% 8,0% 6,1% 
Urinary tract infection (SAE) 
       
0.2% 
  
           
Leucopenia and lymphopenia 
   
6.9% 
      
Leucopenia 
        
2,8% 
 
Lymphocyte count decreased 
     
12.4% 
    
Lymphocyte count decreased (SAE) 
     
4.2% 
    
Lymphopenia 
  
1.24% 3.8 
 
1.6% 2.3% 12.0% 4,2% 0,2% 
Lymphopenia (SAE) 0.3% 
    
0.5% 
 
0.2% 0,5% 
 
Lymphadenopathy 
          
White blood cell count decreased 
     
5.7% 
    
White blood cell count decreased (SAE) 
     
2.6% 
    
           
Angina pectoris (SAE) 
 
1 (0.0%) 
        
Atrioventricular block 
  
0.25% 
       
Atrioventricular block (SAE) 
     
0.5% 
    
Atrioventricular block first degree (FDO) 
      
0.3% 
   
Atrioventricular block first degree 
      
0.3% 
 
0,5% 
 
Atrioventricular block first degree (SAE) 
     
0.5% 
 
0.1% 
 
0,2% 
Atrioventricular block second degree 
     
0.9% 0.1% 
   
Atrioventricular block second degree (SAE) 
 
0.2% 
   
0.9% 
 
0.1% 
 
0,2% 
Blood pressure decreased 
     
0.6% 
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Cohort 
EPOC260,262 FIRST208 
Gilenya* Go 
Program(TM)
172 
LONGTERMS209,
210 
Multicentre 
Sweden230 
Multicentre 
Japan204 
PASSAGE214 
Phase III 
studies44 
FREEDOMS
38 
TRANSFORMS
48 
Bradyarrhythmia occurring post-first dose 
   
2.0 
  
3.5% 
   
Bradycardia FDO 
          
Symptomatic bradycardia FDO 
          
Bradycardia 2.2% 0.6% 0.2% 
  
3.1% 1.3% 
   
Bradycardia (SAE) 
 
1 (0.0%) 
 
0.1 
 
1.5% 0.4% 0.4% 0,9% 0,5% 
Bradycardia, bradyarrhythmia, or sinus 
bradycardia         
2,1% 0,5% 
Cardiac disorder 4.3% 
 
0.06% 
 
0.37% 
     
Cardiac disorder (SAE) 
 
1 (0.0%) 
  
0.73% 
     
Cardiac flutter 0.3% 
         
Cardiovascular disorder 
 
0.1% 
        
Cardiovascular disorder (SAE) 
 
1 (0.0%) 
        
Chest pain (SAE) 
       
0.2% 0,9% 
 
Hypertension 5.5% 
  
3.0% 
  
1.3% 8.8% 6,1% 3,7% 
Diastolic blood pressure  ≥ 15mmHg increase vs 
BL        
29.6% 
  
Diastolic blood pressure increase ≥ 100mmHg 
       
7.6% 
  
Systolic blood pressure  ≥ 20mmHg increase vs 
BL        
34.1% 
  
Systolic blood pressure increase ≥ 160mmHg 
       
4.8% 
  
Heart rate decreased 
     
1.4% 
    
Heart rate decreased (SAE) 
     
0.4% 
    
Ischaemic and haemorrhagic strokes (SAE) 
       
0.2% 
  
Palpitations 1.5% 0.6% 
        
QT interval prolongation 
   
0.7 
      
Sinus bradycardia 
     
0.6% 
    
Sinus bradycardia (SAE) 
 
1 (0.0%) 
   
0.4% 
    
Tachycardia 
 
0.1% 
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Cohort 
EPOC260,262 FIRST208 
Gilenya* Go 
Program(TM)
172 
LONGTERMS209,
210 
Multicentre 
Sweden230 
Multicentre 
Japan204 
PASSAGE214 
Phase III 
studies44 
FREEDOMS
38 
TRANSFORMS
48 
Thromboembolic events 
   
0.9 
  
0.5% 
   
Ventricular extra systoles 
 
0.2% 
        
Posterior reversible encephalopathy syndrome 
(SAE)        
0.1% 
  
Pulmonary edema 
   
0.1 
      
           
Alanine amino transferase increased 2.4% 
  
2.7 
 
1.8% 1.3% 11.2% 
 
6,5% 
Aspartate aminotransferase increased 
     
0.6% 0.6% 
   
Bilirubin 
       
8.7% 
  
Liver disorder 
     
1.5% 
    
Liver dysfunction 
     
5.1% 
    
Liver dysfunction  (SAE) 
     
1.4% 
    
Liver enzyme elevation 
   
5.8 
  
3.5% 
   
Liver function test abnormal 
     
2.5% 
  
15,8% 
 
Liver function test abnormal (SAE) 
     
0.4% 
  
0,5% 
 
γ-glutamyltransferase increased 
   
1.8 
 
3.5% 1.1% 
   
γ-glutamyltransferase increased (SAE) 
     
0.4% 
    
           
Bronchoconstriction 
   
2.1 0,13% 
     
Cough 
       
12.8% 10,1% 4,7% 
Dyspnea 
   
2.0 
    
7,1% 1,9% 
Oropharyngeal pain 
        
6,8% 
 
Nasal congestion 
          
           
Basal-cell carcinoma (SAE) 
   
0.5 
   
1.6% 0,9% 0,7% 
Breast cancer (SAE) 
      
0.2% 0.3% 
 
0,7% 
Malignant melanoma (SAE) 
       
0.2% 
 
0,7% 
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Cohort 
EPOC260,262 FIRST208 
Gilenya* Go 
Program(TM)
172 
LONGTERMS209,
210 
Multicentre 
Sweden230 
Multicentre 
Japan204 
PASSAGE214 
Phase III 
studies44 
FREEDOMS
38 
TRANSFORMS
48 
Melanocytic nevus 
   
2.8 
     
6,5% 
Other malignant neoplasms 
   
0.4 
  
0.5% 
   
Ovarian epithelial cell cancer (SAE) 
       
0.1% 
  
Pancreatic carcinoma 
      
0.1% 
   
Skin cancer 
   
0.7 
  
0.1% 
   
Squamous cell carcinoma of the skin (SAE) 
       
0.1% 
  
Thyroid malignancy (SAE) 
   
1 (0.0) 
      
Uterine leiomyoma (SAE) 
       
0.4% 
  
           
Fatigue 11.5% 
  
3.7 
  
2.0% 10.7% 11,3% 10,3% 
MS relapse 
   
0.6 
 
1.1% 0.6% 
   
MS Relapse (SAE) 0.6% 
  
0.3 
 
0.9% 0.6% 0.8% 0,9% 
 
MS symptoms worsening 
  
0.76% 
       
           
Headache 12.4% 
 
0.71% 9.9 
 
0.7% 2.5% 26.5% 25,2% 23,1% 
Migraine 
   
1.5 
      
Migraine (SAE) 0.3% 
         
Dizziness 6.4% 
  
2.5 
    
7,3% 5,6% 
Paraesthesia 
        
5,4% 
 
Syncope (SAE) 
          
Convulsion (SAE) 
          
Epilepsy (SAE) 
       
0.1% 2,1% 
 
           
Diarrhea 5.2% 
  
4.2 
 
1.0% 
 
13.6% 11,8% 7,5% 
Nausea 6.1% 
  
3.5 
 
1.2% 
 
()/(425+ 8,9% 9,3% 
Vomiting 
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Cohort 
EPOC260,262 FIRST208 
Gilenya* Go 
Program(TM)
172 
LONGTERMS209,
210 
Multicentre 
Sweden230 
Multicentre 
Japan204 
PASSAGE214 
Phase III 
studies44 
FREEDOMS
38 
TRANSFORMS
48 
Dyspepsia 
          
           
Arthralgia 
   
3.0 
    
7,1% 2,8% 
Back pain 
   
4.2 
   
12.0% 11,8% 6,1% 
Back pain (SAE) 
       
0.2% 
  
Pain in extremity 
        
6,6% 
 
Myalgia 
         
3,3% 
Limb pain 
         
4,9% 
Neck pain 
          
           
Depression 
   
3.4 
    
7,8% 4,9% 
Depression (SAE) 
        
0,5% 
 
Major depression (SAE) 
          
Anxiety 
          
Insomnia 
   
2.4 
    
4,9% 
 
           
Abdominal pain (SAAE) 
          
Cholelithiasis (SAE) 
       
0.4% 
  
Nephrolithiasis (SAE) 
   
0.1 
      
Decreased renal function 
   
0.3 
      
Hypercholesterolemia 
        
5,6% 
 
Weight increase 
        
3,3% 
 
Vertigo 
        
4,2% 
 
Death (SAE) 
      
0.1% 0.2% 
  
Fever (SAE) 
    
1,04% 0.4% 
   
4,2% 
Influenza-like illness 
         
3,5% 
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Cohort 
EPOC260,262 FIRST208 
Gilenya* Go 
Program(TM)
172 
LONGTERMS209,
210 
Multicentre 
Sweden230 
Multicentre 
Japan204 
PASSAGE214 
Phase III 
studies44 
FREEDOMS
38 
TRANSFORMS
48 
Itchiness 
  
0.06% 
       
Macular edema 0.9% 
 
0.35% 0.2 
 
0.7% 0.6% 0.4% 
  
Macular edema (SAE) 
     
0.5% 
 
0.2% 
  
Patients treated for macular edema 
       
0.2% 
  
Muscular weakness 
     
0.6% 
    
Muscular weakness (SAE) 
     
0.5% 
    
Non-cardiac chest pain (SAE) 0.3% 
      
0.2% 
  
Physical weariness 
     
1.7% 
    
Pregnancy 
      
0.3% 
   
Reproductive toxicity 
   
0.9 
      
Abortion 
          
AEs – Adverse Events; BL – Baseline;  FDO – First Dose Observation; SAEs – Serious Adverse Events 
  
73 
 
4.4. Discussion 
4.4.1. Studies analysed and limitations of this review 
When well designed a retrospective study is as valid as a prospective one. If in 
everyday clinical practice all the right evaluations are systematically registered, there is no 
reason to obtain different results between a prospective and retrospective study following 
the same cohort in the same time window. The (bad) reputation that sometimes 
retrospective studies have is mainly due to poor designs or incomplete data in the source 
documents. The high percentage of retrospective studies reviewed here, representing 
approximately  40% of the patients, shouldn’t bring per se any reduction in the validity of its 
results. 
Cohorts from well identified centres, from studies done individually or with other well 
identified centres, account for 54.7% of the studies, but only for 14.8% of the patients. The 
remaining studies and patients are multicentre studies, national or multinational, and 
registries.  
Due to the nature of studies done in the clinical practice setting it is easier and 
financially more feasible to do comparative studies than active controlled randomized trials. 
But, at the end of the day, is the evidence that everyone wants to know. I was surprised to 
see that only 12.6% of the studies reviewed, had a control cohort. These studies followed 
2,384 fingolimod patients. Without any surprise, most of these studies included natalizumab 
as control. (Figure 16)    
 
In this review I wanted to 
gather as much real world data as 
possible and thus very inclusive 
criteria was used to select the studies 
to be reviewed. In clinical trials we 
have a very homogeneous 
population, which guarantees high precision of the results and high internal validity. This 
Figure 16. Control used in comparative studies 
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strategy results, most of the times, in studies with a less than perfect external validity. On 
the other hand, studies in the clinical practice setting usually have a more heterogeneous 
population, resulting in a lower internal validity, but with a higher external validity. My belief 
is that, even though when considered individually these studies can’t be used to reach any 
conclusion about the treatment effectiveness due mostly to small samples, when considered 
as a whole they become more robust and credible to be used to reach drug effectiveness 
deductions. 
In this work, I wasn’t able to review references in other languages than Portuguese, 
English, Spanish and French. Poster and abstracts that were not available online, or that I did 
not have the opportunity to see in the respective congress, were naturally excluded from 
this review. Regarding oral presentations I have only considered its abstracts, when 
published online. I believe that, even with all these exclusions, I have captured a big 
proportion of RWE data shared by clinicians in congresses and peer-reviewed journals. 
Individual comments and conclusions of each study are summarized in Table 15.
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Table 15. Key takeaways for each study 
Cohort Country Focus Comments 
REAL Argentina Registry Interim results of Argentinian registry with 48 patients; 8.5 months FU; 97.9% relapse-free 
Multiple Sclerosis 
Treatment Registry 
Austria 
FTY vs 
NTZ 
Austrian registry; 312 patients (NTZ 1208); 21.5month FU; 54.2% of FTY patients have been previously treated 
with NTZ. From these patients, the ones treated for at least one year with FTY (n=72), had an increase of ARR 
from 0.3 to 0.5 and the EDSS changed from 3.6 to 3.9 (NTZ cessation) and stayed stable during FTY treatment at 
3.8. 72.9% ARR reduction (inferior vs NTZ); disability stable or improved in 78% (NTZ 85%); 59% of persistence 
(NTZ 60%) 
São Paulo Brazil FDO Retrospective FDO study with 180 patients; 89.4% patients discharged after 6h; 
Gilenya* Go Program(TM) Canada PRO 
Patient program registry with 1,700 patients;  0.29% AV block; 0.17% bradycardia;  99.3% continued on 
treatment post-FDO; 85.5% of persistence 
Multiple Sclerosis Registry Denmark FDO 
FDO retrospective study with 496 patients; 32.3% with NTZ as previous treatment; >3month FU; Cardiac adverse 
effects occurred at a similar rate as in clinical trials and did not require treatment. Most respiratory symptoms 
resolved spontaneously on continued FTY treatment, but 2 patients had to discontinue treatment. 3.9% 
required prolonged cardiac monitoring; 89.2% of persistence; 
Alsace France 
NTZ 
switch 
Data extracted from 1 abstract + 1 letter to the editor; Retrospective study with 59 patients; 6.8 weeks WO; 
7month FU; NTZ switch; 81.4% relapse-free patients similar to PTs, but for those patients with WO> 12weeks 
only 50% were relapse-free; 94.9% of persistence; 
Alsace France Efficacy 
Retrospective regional study with 290 patients; 12month FU; high EDSS at BL (3.6); 0.17 ARR; 70.5% ARR 
reduction; 4.1 months to 1st relapse; 82.4% relapse-free; +0.1 EDSS difference vs BL; 89.7% of persistence; 
Bordeaux France FDO 
Prospective study with 24 patients; 3month FU;  82.6% relapse-free; 4.2% treatment discontinuation after FDO; 
91.7% of persistence; 
ENIGM France 
NTZ 
switch 
NTZ switch; survey-based; 333 patients; 31 NTZ infusions; 71% JCV+; 27% patients relapsed in the WO period 
(17 weeks); 80% relapse-free patients; the percentages of patients who relapsed depending on the WO were 
19.9% for less than 3 months, 31.3% for 3 to 6 months, and 59.1% for greater than 6 months; switching from 
NTZ to FTY was associated with a risk of MS reactivation during the WO or shortly after FTY initiation. The WO 
should be shorter than 3 months. 97% of persistence; 
GRACE France PRO 
Prospective study with 198 patients; The BL level of anxiety was not high before FTY treatment initiation  (HADS 
8.8), but decreased even further within 4 months of treatment (HADS 8.1); (8.8 vs 8.1; p=0.001) 
Reims France Efficacy 
Prospective study with 66 patients; 11month FU,  51.5% patients with >12month; 59.1% ARR reduction; 68.3% 
relapse-free; 84.8% MRI lesions-free; 89.1% Free of relapse and T1Gd+ 
Dresden Germany FDO 36 patients; Most CV effects are only short-lived during the first day of FTY administration. 
Munich, Bochum, 
Marburg 
Germany 
NTZ 
switch 
Retrospective NTZ switch study with 33 patients; 31.8 NTZ infusions; 20.3month FU; EDSS >3 after switch of NTZ 
is a predictor for relapses during subsequent FTY therapy; 75% of patients with EDSS ≤3 remained relapse-free; 
patients with EDSS ≤3 ARR 0.24 vs EDSS>3 ARR 1.35; ARR during NTZ did not significantly influence relapse 
activity during FTY; +0.1 EDSS difference vs BL 
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NeuroTransConcept Germany 
FTY vs 
NTZ 
Retrospective study with 190 patients; 12month FU; Switch from DMT to FTY or NTZ; Clinical efficacy of FTY and 
NTZ in RRMS second-line-therapy was similar during the first 12 months of treatment. Disability stable or 
improved in 80.5% (NTZ 79.3%); -0.14 EDSS difference vs BL (NTZ -0.13); 70.6% ARR reduction; 75.8% relapse-
free (NTZ 72.3%); 71.1% Free of relapse and EDSS progression (NTZ 62%) 
PANGAEA Germany 
Large 
open 
trials 
Prospective study with 3641 patients; data extracted from 3 different posters; <24month FU; 18.4% with NTZ as 
previous treatment; NTZ patients 66.92% JCV+; A short NTZ wash-out period is associated with lower clinical 
reactivation. The relapse activity in the first half year of PANGAEA highly depends on the length of the NTZ WO 
phase prior the FTY first dose. 2.63% patients hospitalized in the past 3 months (PEARL active 8.02%). 14.02% 
patients took sick leave in the past 3 months (PEARL active 35.94%). Superior ARR reduction vs IFN/GA; 
disability stable or improved in 94%; -0.07 EDSS difference vs BL (PEARL +0.5); 1.7% cardiac AEs; 0.77% 
prolonged monitoring; >96.0% of patients and physicians rated FTY tolerability as good or very good. >94.1% 
physicians and 96.9% of patients rated FTY tolerability as good or very good; >90.7% physicians 89.5% of 
patients rated FTY effectiveness as good or very good. 83.4% of persistence; (PEARL active 63.2%; PEARL 
inactive 85.9%); 0.5 days without MS medication within 2 weeks (PEARL active 1.6) 
START Germany FDO 
Prospective FDO study with 1640 patients; Main analysis + subgroup analysis for patients also treated with 
SSRIs; 91.2% discharged after 6h; 1% required overnight monitoring; 12bpm average maximum decrease of 
heart rate; 4bpm average decrease of heart rate 6h after FTY first dose; nadir Heart Rate at 4.1; 99% with heart 
rate >45bpm at any time;  Within the first 6 hours the heart rate returned to 93 % of the baseline level; 3.6% 
with de novo 1st degree AVB; 1.6% 2nd degree or higher AVB; similar results between the main analysis and the 
SSRIs subgroup 
Athens Greece 
NTZ 
switch 
NTZ switch study with 60 patients; 33.3% with NTZ as previous treatment; >12month FU; 10/60 patients treated 
with monthly MP in the WO period; 93.3% relapse-free 
Ramat-Gann Israel Efficacy 
Retrospective study with 110 patients; 20month FU; Discontinuation due to adverse events occurred within the 
first year of treatment. ARR  0.35; 76.4% patients continued on treatment; 
Tel-Aviv Israel Other 
Data extracted from 2 different posters; Prospective study with 30 patients; 12month FU; Gilenya treatment 
demonstrated preservation of structural thickness over one year of treatment. A numerical increase has been 
observed in all but one cognitive measure. The lack of statistical significance may be due to the very small 
sample. Gilenya treatment demonstrated preservation of structural thickness over one year of treatment. no 
difference in EDSS vs BL. 
Ferrara, Parma 
Modena, Reggio-Emilia, 
Fidenza and Piacenza 
Italy Efficacy 
127 patients; 10month FU; Confirms the efficacy of FTY in reducing relapse rate in patients previously treated 
with DMTs, while it seems to be less effective in patients discontinuing NTZ. 30.7% patients previously treated 
with NTZ; 18 weeks WO;  ARR 0.28; 76.7% ARR reduction; 20.2% improvement in MRI lesions-free; 14.6% 
improvement in T1Gd+ lesions-free; WO period may have been too long. No difference in EDSS vs BL. In PNTZ 
0.1 difference vs BL, p= 0.14) 
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Cohort Country Focus Comments 
Gallarate Italy Other 
55 patients; 12month FU; 21.8% patients with NTZ as previous treatment; 67.3% Free of relapse and EDSS 
progression; Active patients had more relapses before FTY (1.8 Vs 1.5, p = 0.043), a lower mean white blood cell 
count (5043.9/mm3 Vs 5328.8/ mm3, p = 0.027) and a lower mean lymphocyte count (653.8/mm3 Vs 
756.8/mm3 , p = 0.05) compared to disease-free patients. 69.1% MRI lesions-free. 67.33% patients free of 
relapse and EDSS progression. Maybe, excessive lymphopenia could include "protective" cell subsets. 
Gallarate Italy 
NTZ 
switch 
NTZ switch study with 32 patients; 21 NTZ infusions; 15.6 weeks WO; 73.3% patients with >6month FU; 28.1% 
relapse-free patients;  long WO (15.6 weeks); 28.1% relapse-free; 96.7% MRI-lesions free; 70% free of relapse 
and EDSS progression 86.7% of persistence; 
iMedWeb registry Italy 
NTZ 
switch 
Retrospective NTZ switch study with 106 patients; 26.4 NTZ infusions (DMTs 19.4); The relapse risk was 4 and 15 
time higher in patients with WO length 1.5-4.4 M and >4.4 M, respectively, in comparison to patients with WO 
<1.5 M.  FTY is more effective than other DMTs in reducing the risk of relapse after NTZ stop (IRR=0.56, 
p=0.0019). The cumulative probability of first relapse was significantly lower in patients receiving FTY than in 
those receiving other DMTs (p=0.021). 
L' Aquila, Pozzilli, Foggia Italy Efficacy 
142 patients; 19.7% with NTZ as previous treatment; 15month FU; 90.8% relapse free (NTZ 82.1%); 82.8% MRI-
lesions free; disability stable or improved in 87.1%; 72.5% Free of relapse, EDDS progression and MRI; 79.7% 
Free of relapse and EDSS progression activity 
L' Aquila, Pozzilli, Foggia Italy 
FTY vs 
NTZ 
Prospective study with 100 patient; 12month FU; NTZ patients in a more advanced state of disease in the BL 
(ARR +0.7; MRI activity +12%; EDSS +0.3); FTY numerically superior in relapse-free patients vs NTZ  (93% vs 
87%); 75 %  MRI lesions-free patients (NTZ 93%); no difference in disability outcomes vs NTZ; disability stable or 
improved in 99% (NTZ98%); 70% Free of relapse, EDDS progression and MRI activity (NTZ 79%) 
Milan Italy 
NTZ 
switch 
NTZ switch study with 61 patients; >6month FU;  Increase of the ARR in the WO period (1.20 vs 0.15, p < 
0.0001); after FTY the ARR had a significant reduction (0.50 vs 1.20, p = 0.0006); after FTY EDSS maintained 
stable (0.15 on NTZ; 0.43 WO period); 
Milan Italy 
FTY vs 
NTZ 
Prospective study with 37 patients; >12month FU; 72.9% ARR reduction (NTZ 96.9%); ARR 0.26 (NTZ 0.04; p< 
0.0001) no difference in disability outcomes vs NTZ; 68% Free of relapse and EDSS progression (NTZ > 92%, p= 
0.003); 42% Free of EDDS progression and MRI activity (NTZ> 93%, p= 0.0003); At 24 month 81% of persistence  
(NTZ 58%); 26% patients  improved in cognitive tests (NTZ 7%); 
Multicentre Italy Italy FDO 
Prospective FDO study with 906 patients; 24.3% with NTZ as previous treatment; 3.14month FU; 95.3% patients 
with uneventful FDO; 1.3% bradycardia; 0.1% 1st degree AVB; 0.2% 2nd degree AVB; 0.1% palpitations; 0.1% 
sinus arrhythmia; 0.1% ventricular premature beats; 95.7% discharged after 6h; 96% of persistence 
Naples Italy FDO 
FDO study with 112 patients; 20.5% with ECG abnormalities pre-FTY; HR decrease was lower than expected with 
terminal ECGs showing a small increase in PR interval. 0.9% symptomatic bradycardia (with headache and lower 
limbs weakness);  1.8% 2nd degree AVB; 16.4% sinus bradycardia, 9.1% right bundle branch block, 9.1% 
ventricular extrasystole, 3.6% 1st degree AV block; 
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Orbassano Italy 
NTZ 
switch 
Retrospective NTZ switch study with 35 patients; >12 weeks WO; Treatment arms after NTZ: FTY, No Treatment 
(NT), and Treatment (T) with other DMTs or immunomodulating agents; OT = NT + T; +0.2 EDSS difference vs BL 
(OT 0.5, p NS); 68.6% relapse-free (OT 58.2%) 
Padua Italy 
NTZ 
switch 
NTZ switch study with 21 patients; 12 weeks WO; 3 month WO period following NTZ exposes patients to disease 
reactivation particularly during the 1st month of FTY. Only patients having a very active disease seem not to 
respond to FTY. FTY was capable to control disease activity in the majority of the patients (>70%). 71.4% 
relapse-free; 52.4% MRI-lesions free; 47.6% Free of relapse and MRI activity; 
Rome Italy FDO 
Prospective study with 55 patients; Significant correlations between measures of parasympathetic function and 
FTY-induced bradycardia. Subjects with higher Valsalva ratio and HR variation during deep breathing had nadir 
HR ≤ 50 bpm after the first FTY dose. Significant negative correlations were found between measures of 
sympathetic function and FTY-induced PR interval increase. Subjects with lower LFnu at rest and less increase of 
blood pressure on the handgrip test showed a PR interval increase > 20 ms after FTY. -14.8% HR at nadir; nadir 
at 4h; 5.5% 1st degree AVB; 1.8% 2nd degree AVB; 
Turin Italy Other 
Prospective study with 35 patients; 6month FU; 2.9% de novo headache; FTY might represent an important 
trigger of transient migraine worsening, but the mechanisms underlying this phenomenon are still unknown. 
Multicentre Japan Japan Registry 
Japanese registry with 837 patients; ARR 0.3; 69.4% ARR reduction; 3.1% bradycardia, 1.4% HR decreased, 0.9% 
2nd degree AVB; 
Tokyo Japan Efficacy 44 patients; 95.5% relapse-free patients; 75% persistence 
Kuwait city Kuwait Efficacy 
Retrospective study with 76patients; 18.5month FU; FTY is safe and effective in reducing clinical and radiological 
disease activity in relapsing remitting MS patients. 64.4% more patients relapse-free vs baseline (p< 0.001); 
60.5% more patients MRI lesions-free vs baseline (p< 0.001); disability stable or improved in 64.5%; -0.98 EDSS 
difference vs BL (p< 0.0001); 94.7% of persistence 
MS registry Kuwait Kuwait Efficacy 
Retrospective study with 175 patients; 21.7months average FU; FTY treatment was associated with reduced 
relapse and MRI activity, and an improved EDSS score. Discontinuation/switch rates and adverse events were 
low. 54.3% more patients relapse-free; 58.4% more patients MRI lesions-free; disability stable or improved in 
92%; -0.34 EDSS difference vs BL (p= 0.03); 88.6% of persistence 
FIRST Multinational FDO 
Prospective FDO study with 2,417 patients; 4month FU; Main analysis + subgroup analysis for patients with or 
without pre-existing cardiac conditions + subgroup analysis for patients with or without concomitant treatment 
with BBs/CCBs; 9.3 years since onset of symptoms of MS ; 96.7% discharged at 6h; 1.3% HR< 45bpm; 94.4% of 
persistence; there is no increased risk of symptomatic or serious cardiac events during treatment initiation in 
patients with PCCs or in those receiving BBs/CCBs 
LONGTERMS Multinational Safety 
Data extracted from 2 different posters; Extension clinical trials; 1665 patients; There were no new safety 
signals detected with the long-term use of fingolimod. 
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Cohort Country Focus Comments 
MSBase Registry Multinational 
NTZ 
switch 
Retrospective NTZ switch study with 89 patients; 7.6month FU; NTZ switch; 95% with WO < 16 weeks; average 
WO 11.1weeks; 79.8% relapse-free; 30% of patients with disease activity on NTZ relapsed within the first 6 
months on FTY; patients who had a gap in treatment of 8-16 weeks were more likely to have a relapse on FTY 
than switchers without WO, p = 0.040; recommendation of 2 months maximum WO 
MSBase Registry Multinational 
FTY vs 
NTZ 
MS Base registry; 171 patients; 12month; Matched cohort; 72.1% ARR reduction (NTZ 87.6%); ARR 0.36 (NTZ 
0.19); disability outcomes favoured NTZ 
MSBase Registry Multinational 
FTY vs 
DMTs 
MS Base registry; 148 patients; 11month FU; Matched cohort; 76.9% ARR reduction (DMTs 62.5%); superior 
proportion of relapse-free patients vs DMTs (HR= 0.74; p= 0.04); ARR 0.3 (DMT 0.45; p= 0.009); superior 
proportion of patients free from disability progression vs DMT (HR= 0.53; p= 0.02); superior proportion of 
patients with reduced disability vs DMT (HR= 2; p= 0.005); Persistence on FTY was better compared to DMT (HR 
0.55; p= 0.04) 
PASSAGE Multinational 
Large 
open 
trials 
interim analysis Post-Approval Safety Study with 1596 enrolled patients; 19.6% with NTZ as previous treatment;  
9month FU; 3.5% bradyarrhythmia (1.3% bradycardia; 0.3% 1st degree AVB; 0.1% 2nd degree AVB) 
Warsaw Poland Efficacy 
11 patients; 12month FU; abstract very incomplete; Polish article; abstract in English; 100% relapse-free; 
disability stable or improved in 90.9%; 100% of persistence 
Coimbra Portugal 
NTZ 
switch 
NTZ switch study with 29 patients; 28.7 NTZ infusions; 9.2 weeks WO; 17.4 months FU; 55.2% relapse-free; a 
higher ARR previous to FTY it's associated with relapse risk during FTY (p= 0.04); 69% with similar or improved 
ARR vs BL;  +0.1 EDSS difference vs BL (p= 0.6); 79.3% of persistence; 
Guaynabo Puerto Rico Efficacy 
retrospective study with 50 patients; 12month FU; 86% free of new black holes; 90% free of Brain Volume Loss; 
2% with Brain volume loss and black hole; FTY can reduce the development of T1 hypo intense-black holes and 
cerebral atrophy in Hispanic population with MS. 
Guaynabo Puerto Rico FDO 
Retrospective study with 25 patients; 6month FU; At FDO no significant cardiovascular events; 100% discharged 
after 6H; 
Moscow Russia Efficacy 11 patients; abstract very incomplete; 82% relapse-free 
Prešov 
Slovak 
Republic 
NTZ 
switch 
NTZ switch; 9 patients; no report of FU period; 24.1 NTZ infusions; 13.2 weeks WO; 44.4% relapse-free, 11.1% 
had MRI reactivation and 11.1% had disease rebound during WO; 
Alicante Spain 
NTZ 
switch 
NTZ switch; 8 patients; 29.4 NTZ infusions; 12 weeks WO;  9.35month FU; 37% relapse-free; ARR (1.88 pre-NTZ; 
0.13 during NTZ; 0.63 during FTY); T2 lesion free 50%; T1Gd+ lesion-free 37.5%; disability stable or improved in 
62.5%;  +1.0 EDSS difference vs BL 
Granada Spain FDO 
Retrospective study with 42 patients; FDO reported by MS nurse team; 95.2% asymptomatic bradycardia; 11.9% 
required prolonged monitoring after the 6h; 98% of persistence 
Hospital Ntra Sra Valme, 
Seville 
Spain 
NTZ 
switch 
NTZ switch study with 49 patients; FTY increased the relapse-free patients from 59.2% to 75.5% and kept 44.9% 
patients free of MRI activity and 75.5% of patients free of disability progression 
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Hospital Universitario 
Virgen Macarena, Seville 
Spain Efficacy 
Retrospective study with 47 patients; 36.5% with NTZ as previous treatment; 16.3 month FU; the response to 
FTY in real world practice supports FTY efficacy in the clinical practice. 71.6% ARR reduction (PNTZ 44.3%); +0.04 
EDSS difference vs BL; 63.8% Free of relapse and EDSS progression 
Multicenter1 Spain Spain FDO 
Prospective study with 148 patients; 6.1month FU; 9.5% average decrease of heart rate 6h after FTY first dose; 
1.2mmHg decrease in systolic BP; 3.5mmHg decrease in diastolic BP; 100% of persistence 
Multicenter2 Spain Spain Registry 
Spain registry  with 267 patients; 27% with previous NTZ treatment; 13.1month FU; 11.5years since onset of 
symptoms of MS. 85.3% JCV+; 88.4% discharged at 6h; mean monitoring time 7.3 hours;  80% relapse-free;  
69.8% of patients free of disability progression; 56.3% Free of relapse and EDSS progression; 96.6% of 
persistence; 
Murcia Spain 
NTZ 
switch 
NTZ switch study 12month; 15.4month FU; small sample; 31 NTZ infusions; WO with MP monthly; 86.4% 
relapse-free after 15.4 months; 100% T1Gd+ lesion-free; no difference in EDSS vs BL. 
Murcia Spain FDO 
Prospective FDO study with 18 patients; 5.56% symptomatic bradycardia; asymptomatic ECG changes were 
observed at 6 (44%) and 24 hours (20%) after first dose of FTY; no clinical or ECG effects requiring FTY 
discontinuation. 
Santiago de Compostela Spain Efficacy 
Retrospective study with 101 patients; 30% with previous NTZ treatment; FTY demonstrated efficacy in  94% of 
patients; only six of them (5,9%) had more relapses and/or disability progression. 30% of patients previously 
treated with NTZ; disability stable or improved in 94%; 96% of persistence 
Valencia Spain 
NTZ 
switch 
NTZ switch study with 11 patients; 37.9 NTZ infusions; 9 weeks WO; 11.7month FU; small sample; WO with MP; 
ARR 0.09 after 11.7 months and 90.9% patients relapse-free; 81.8% T1Gd+ lesions-free; -0.3 EDSS difference vs 
BL; 90.9% of persistence 
MS registry Sweden Sweden 
FTY vs 
NTZ 
Sweden registry; 628 patients; 48.1% with NTZ as previous treatment; >12month FU; Time since onset of 
symptoms of MS (years) 9.9 (NTZ 7.1; NTZ-naïve 8.9). Treatment discontinuation rate for FTY was higher than 
for NTZ, which entirely is explained by a higher drop-out rate for NTZ experienced FTY patients. 82.3% of 
persistence (NTZ 86.6%; NTZ-naïve 86.9%) 
Multicentre Sweden Sweden Registry 
Prospective study with 674 patients; 33% with NTZ as previous treatment; 12month FU; The clinical measures 
improved vs BL; EDSS (+ 0 %), MSSS (- 12.2 %), SDMT (+ 8.7 %), MSIS-29 physical/psychological scores (-7.4% and 
-13.3%, respectively) EQ-5D (+ 6.3 %). Blood lymphocytes values were registered throughout the treatment (x 
109/L); no difference in EDSS vs BL. 0.59% cardiac disorders (bradycardia, AV-block, hypertension); 89.6% of 
persistence; 
Basel Switzerland 
NTZ 
switch 
NTZ switch study with 15 patients; 41.4 NTZ infusions; 8 weeks WO; 8month FU; 100% JCV+; 46% relapse-free; 
46.2% T2 and T1Gd+ lesion-free; Clear pattern of increasing disease activity after alpha4-integrin desaturation. 
Preliminary analysis revealed increased TNF-α and IL-8 after stopping of NTZ. Autoantigen and viral antigen 
specific IFNγ production peaked after stopping NAT and decreased upon FTY start. A shorter wash out period is 
more suitable for switching patients safely. Very small sample; 86.7% of persistence; 
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SWISSASCENT Switzerland PRO 
212 patients; 28% with NTZ as previous treatment; 8.3month FU; ARR 0.2; 75% ARR reduction; 88% relapse-
free; QoL (MSIS-29) remained stable over time in patients switching from other DMTs but those patients 
showed a significant improvement in the mental subscore; Treatment satisfaction improved 14 points upon 
switch from other DMTs to FTY (p= 0.001). This was true for all domains of the TSQM-9 scale. 75% ARR 
reduction; 99.5% patients did not require any medical intervention, nor monitoring on day two (98%), and 
continued FTY treatment after the FDO (99.5%); 96% of persistence; 
Istanbul Turkey Efficacy 
Prospective study with 109 patients; 5.5month FU; 90% relapse-free; 8.3% relapsed in the 1st 3 month, 1.7% 
relapsed more than 3 month after initiation;  94.5% persistence 
Wimbledon UK FDO 
FDO study with 143 patients; 94% discharged at 6h; 4% extended monitoring and  discharged at 8h; 1% 
overnight stay for symptomatic bradyarrhythmia; 
Boston USA Efficacy 
Retrospective study with 177 patients; 15.3% with NTZ as previous treatment; >12month FU; no demographic 
feature was significantly associated with time to first event in patients treated with FTY; 83.6% relapse-free; 
85.9% free of MRI activity; disability stable or improved in 75.7%; 87.6% Free of relapse and MRI activity; 50.3% 
free of relapse, EDDS progression and MRI activity 
Boston USA FDO 
Retrospective FDO study with 305 patients; 84.6% of persistence; -14 bpm at nadir; 98.7% FDO uneventful; 
0.66% 2nd degree AVB; 
Cleveland Clinic USA FDO 
Retrospective study with 317 patients; 3.3month FU; There were no significant differences in T25FW, PHQ-9, 
MSPS or EQ5D (n=164) compared to baseline. FDO uneventful in 97.8%; 90.5% of persistence; 
Cleveland Clinic USA Efficacy 
Study with 306 patients; 11.1month FU; MS performance scale, PHQ9 and EQ5D remained stable; T25FW 
deteriorated; ARR 0.12;  64% relapse-free; 59.3% Free of relapse and MRI activity; 76.1% of persistence; 
Cleveland Clinic USA Efficacy 
Retrospective study with 196 patients; 8.6month FU; 85% stable or improved in T25FW; 91.6% stable or 
improved in 9PHT; -0.03 mean change in PHQ9 (p= 0.06); -0.005  mean change in EQ-5D (p= 0.02);  0.54 mean 
change in MSPS (p= 0.20);  Clinician-derived and patient-reported disability scores and patient-reported QoL 
measures were stable 
Cleveland Clinic USA Other 
Prospective study with 232 patients; 6.4month FU; Small magnitude increases in central subfoveal thickness and 
outer retina thickness may occur on FTY therapy. Decrease in ganglion cell thickness and peripapillary RNFL 
thickness identified over 6 months may relate to the MS disease process. FTY may selectively affect foveal 
measures. Further studies with appropriate controls are needed to elucidate the effect of FTY on macular 
volume and specific retinal layers. 
Cleveland Clinic USA 
FTY vs 
DMF 
Retrospective study with 317 patients; 3 month FU; difference in currently available data for each treatment 
group; 0.03 relapses/patient (DMF 0.12); 97% relapse-free (DMF 89%); similar T1Gd+ lesion-free results; 92% of 
persistence (DMF 82%); 
commercial health plan or 
Part D program 
USA PRO US claims database analysis; Adherence rate similar to NTZ; MPR 75.4% (NTZ 79%) 
  
 
8
2 Cohort Country Focus Comments 
Cullman USA 
NTZ 
switch 
NTZ switch study with 75 patients; >6month FU; 97.3% Free of relapse and T1Gd+; 75% of persistence; 
Houston USA FDO 
Continuous on-line electrocardiographic telemetry may detect abnormal rhythms in a small number of patients 
started on FTY. The clinical significance of these is unclear. 3% bradycardia secondary to atrioventricular 
conduction abnormality; 1.7% sinus bradycardia with accelerated idioventricular rhythm. 
Medco Health Solutions USA PRO 
pharmacy claims; 248 patients; 12month FU; FTY initiators were more compliant, less likely to discontinue 
treatment, and discontinued later; 68.8% of persistence; adherence >87.4% with MPR>0.8 
Multicenter1 USA USA PRO 
Prospective study with 205 patients; 6month FU; Switching to FTY demonstrated improvements in patient-
reported treatment satisfaction, fatigue, depressive symptoms, and physician assessments vs remaining on IFN. 
Multicenter2 USA USA PRO 
Cross-sectional survey with 380 patients; most FTY patients were satisfied with their FDO experience. 
Satisfaction with FTY was high and observed higher among treatment-experienced compared to treatment-
naïve patients. 
Multicenter3 USA USA NRO 
Online survey of 102 neurologists; Among the DMTs available at the time of the survey, neurologists reported 
that patients were most satisfied with, and adherent to FTY 
NARCOMS USA PRO 
50 patients (NTZ 50); 54month FU; PDDS; Transitioning of natalizumab after 2 years was associated with a 
statistically significant increase in the likelihood of participant-reported disability progression and increased 
mean disability. No report of mean washout period. 6 month difference between FTY and NTZ follow up 
Partners MS Centre USA 
FTY vs 
NTZ 
Retrospective study with 38 patients; 18month FU; JCV serology to determine therapy; 44% JCV+; patients 
treated with NTZ had a longer time to relapse (2.20  p = 0.095) in the unadjusted analysis; patients treated with 
NTZ had a significantly lower hazard of a relapse in each model; patients treated with NTZ had a significantly 
longer time to first inflammatory event (relapse or new GD+ lesion) 2.31 p = 0.041; 11.6% JCV seroconversion; 
FTY had a better persistence on treatment; 77.8% of persistence (NTZ 63.8%) 
PharMetrics Plus™ USA PRO 
US claims database analysis; 889 patients; 12 months FU; Persistence with and adherence to FTY compared with 
NTZ, GA and IFN; 72.1% of persistence (GA 60.5%; IFN 56.3%; NTZ 61%; FTY vs all p<0.001); 93.8% with MPR>0.8 
(GA 88.1%; IFN 88.1%; NTZ 88.7%; FTY vs all p<0.001); 89.7% with PDC>0.8 (GA 84.1%; IFN 85.1%; NTZ 86.0%; 
FTY vs all p<0.001); no safety data reported 
PharMetrics Plus™ USA 
FTY vs 
NTZ 
Retrospective study with 185 patients (NTZ 185); 12month FU;  68.1% relapse-free (NTZ 68.6%; p= 0.9110); 71% 
reduction of patients who required an MS-related inpatient admission (NTZ 87%; p= 0.2620); 58% reduction of 
patients who visited an emergency department (NTZ 69%; p= 0.7215); FTY reduced the MS-related outpatient 
claims (p< 0.0001) and NTZ increased the MS-related outpatient claims (p< 0.0001); 71.9% of persistence (NTZ 
76.2%; p=0.3427) 
PharMetrics Plus™ USA 
FTY vs 
DMTs 
US claims database analysis; 132 patients; 12month FU; ARR 0.19 (GA 0.51); 87.1% relapse-free (GA 75%; p= 
0.012); 59% reduction in the probability of having a relapse vs GA (p =0.0091); 360 days median time to 1st 
relapse (GA 274); Patients treated with FTY had 62% fewer relapses per year (p =0.0013); 73.5% of persistence 
(GA 62.9%; p= 0.0643); 
  
 
8
3 
Cohort Country Focus Comments 
PharMetrics Plus™ USA 
FTY vs 
DMTs 
US claims database analysis; 128 patients (DMTs 397); 18month FU; relapse outcomes results superior to 
IFN/GA; 57.0% of persistence (DMTs 45.1%; p=0.0187); 
Seattle USA Other 
Retrospective study with 126 patients; 7month FU; Trend of RNFL and GC-IP thinning was noted but did not 
reach statistical significance. The observed trend in macular volume change was independent of age, gender, 
time since MS diagnosis, or prior history of optic neuritis. FTY-treated MS patients experience a decrease in 
macular volume during the first year of treatment. 
US Lord™ and PharMetrics 
Plus™ 
USA PRO US claims database; 1553 patients; >6month FU; Higher persistence with FTY vs DMF (p< 0.01) 
EPOC USA, Canada FDO 
Prospective study with 976 patients; 6month FU; 18.5% of patients with pre-existing cardiac conditions and did 
an ECG at 6h post-dose. Patients with pre-existing cardiac conditions (PCCs: history of cardiac arrest, myocardial 
infarction, unstable ischemic heart disease, coronary spasm, congestive heart failure, HR <55bpm, sick sinus 
syndrome, sinoatrial heart block, or any factors considered to be cardiac risk factors by the study investigator); 
0.01% with HR< 40bpm; 18.2% with new ECG abnormalities; 98.5% discharged at 6h; 
EPOC USA, Canada PRO 
Prospective study with 847 patients; 6month FU; 50.5% recovered from depression (DMT 25.3%); 8.1% became 
depressed (DMT 9.3%); 
EPOC USA, Canada PRO 
Prospective study with 790 patients; 6month FU; TSQM scores were significantly greater with FTY than with 
DMT (Global satisfaction, Effectiveness, Side Effects, and Convenience; p< 0.0001); Improvements in FSS and 
BDI-II score were  significantly greater with FTY than with DMT (p< 0.0001); PRIMUS Activities score were 
numerically  reduced (better outcomes in fatigue and depression) with FTY versus DMT; SF-36 scores were 
significantly greater with FTY than with DMT (p< 0.0001), except for the domains ‘Physical functioning’ and 
‘General health perceptions’; no relapse, MRI or disability reported data; 90.4% of persistence (DMTs 87.1%) 
EPOC USA, Canada PRO 
Prospective study with 790 patients; 6month FU; therapy switch from DMTs to FTY may improve depressive 
symptoms, particularly somatic concerns 
EPOC USA, Canada Safety 
Prospective study with 783 patients; 6month FU; Lymphocyte counts did not significantly differ by occurrence or 
non-occurrence of specific infection types. The overall incidence of infection was similar in the fingolimod and 
DMT. 
9PHT - 9-Hole Peg Test; ARR - Annualized Relapse Rate; AV – Atrioventricular; AVB - Atrioventricular Block; BBs - Beta Blockers; BDI-II  - Beck Depression Inventory-II; BL – Baseline; BP - Blood Pressure; bpm - Beats 
Per Minute; CCBs - Calcium Channel Blockers; CV – Cardiovascular; DMF - Dimethyl Fumarate; DMT - Disease Modifying Treatments; ECG – Electrocardiogram; EDSS - Expanded Disability Status Scale; FDO - First Dose 
Observation; FSS - Fatigue Severity Scale;  FTY – Fingolimod; FU - Follow-Up; GA - Glatiramer Acetate;  GC-IP - Ganglion Cell/Inner Plexiform; HADS - Hospital Anxiety and Depression Scale; HR - Heart Rate; JCV - John 
Cunningham Virus;  MP – Methylprednisolone; MPR - Medication Possession Ratio; MRI - Magnetic Resonance Imaging;  MS - Multiple Sclerosis; MSFC - Multiple Sclerosis Functional Composite; MSIS - Multiple 
Sclerosis Impact Scale; MSPS - Multiple Sclerosis Performance Scales ; MSSS - Multiple Sclerosis Severity Score; NT - Non-Treated; NTZ - Natalizumab; PDSS Patient Determined Disease Steps; PHQ-9 Patient Health 
Questionnaire 9; PNTZ - Patients who have natalizumab as previous treatment; PTs - Pivotal Trials; QoL - Quality of Life; RNFL - Retinal Nerve fibre Layer; SDMT - Symbol Digit Modalities Test; SSRIs - Selective 
Serotonin Reuptake Inhibitors; T - Treated; T1Gd+ - T1 Gadolinium-Enhancing Lesions; T25FW - Timed 25-Foot Walk;  TSQM - Treatment Satisfaction Questionnaire for Medication; WO - Washout;
 84 
 
4.4.2. Baseline characteristics 
Number of patients is the only baseline characteristic that it is reported by virtually 
every study. Regarding multiple sclerosis outcome measures, a big proportion of studies 
report disability and relapses, but only 6.3% publish MRI baseline data. Almost half of the 
studies reported if natalizumab was the previous treatment and, within those studies, the 
vast around 55% just mention the percentage of patients previously treated with 
natalizumab. (Figure 17) 
 
Figure 17 Baseline characteristics reported by studies 
 
 
Patients in the TRANSFORMS study had, at baseline, mean disease duration of 7.5 
years, 1.5 relapses in previous 12 months (2.3 in previous 24 months); EDSS of 2.24 and 
67.4% of patients did not have T1Gd+ lesions on the MRI. The average patient enrolled in 
these studies had longer disease duration and higher EDSS score, but a lower ARR. If we 
exclude USA studies, considering them as a separate subgroup due to USA’s first line label, 
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the group does not change much, and oddly enough USA patients all have more than 7.5 
years of disease duration. (Table 16) 
Table 16. Reported disease status at baseline. Studies weighted by patients enrolled 
4.4.3. Relapse outcomes 
Relapse outcomes were reported in 48.8% of studies, which enrolled 8,483 patients. 
Generally, the vast majority of studies confirmed fingolimod efficacy in reducing relapse 
activity seen in pivotal trials. The ARR reduction weighted average was 70.1%, and the 
reported ARR reduction was superior to 68% in all but two studies. (Figure 18)  
 
Figure 18. ARR reduction. The bubble size represents the patient numbers 
 
In the studies where natalizumab was used as control, fingolimod seems to be, at least 
as effective as natalizumab when used in second line therapy. Fingolimod reported similar or 
 
Review World USA only 
< Disease duration 8,0% 0,0% 11,0% 
< ARR 63,6% 69,9% 61,5% 
< EDSS 3,3% 7,7% 2,4% 
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superior results in 50% of the studies. When the control was glatiramer acetate, interferon 
or DMF, fingolimod always showed superior relapse outcome results. 
4.4.4. Disability 
It is pretty difficult to summarize disability outcomes in the 29.5% studies that 
reported it. Main reason being the non-standardized approach of how this should be 
reported. In clinical trials, the most common endpoints are:263  
- EDSS score difference vs baseline 
- NRS score difference vs baseline 
- MSFC score difference vs baseline 
- Proportion of patients without confirmed disability progression (confirmed at 3 or 
6 months) 
- Time to progression of disability as measured by EDSS at 12 weeks 
In the clinical practice EDSS is the most commonly used measure of disability. Although 
it’s far from perfect, it’s widely used both in clinical trials and clinical practice because it’s 
easy to apply and it is accepted by the regulatory authorities.  The main problems of EDSS 
scale are its dependence on rater judgement and its main focus on physical disability.  
A total of 13 studies with 5,249 patients reported proportion of patients free of 
disability progression, and fingolimod achieved a weighted average of 89.9% after 13.2 
months. In the 15 studies that reported EDSS difference from baseline, involving 5,212 
patients, the weighted average difference   in the EDSS score   compared to the baseline was 
-0.07, and a similar result is obtained if we exclude the natalizumab switch studies. 
4.4.5. MRI Outcomes 
Measuring MRI outcomes in the clinical practice maybe challenging in some countries, 
where the access to routine MRI exams is restricted based on budgetary issues. 
Furthermore, MRI scanning machines have evolved a lot, in the last decades, and are very 
expensive, and thus aren’t upgraded as much as it would be desirable in some MS centres. 
These two reasons may help to understand why MRI outcomes in the real world are more 
difficult to measure than in clinical trials.   And last, but not least, there are many MS centres 
where there is still some technological issues to overcome to make it easier to monitor MRI 
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lesions or brain volume changes. Automatic or semi-automatic software to count lesions or 
evaluate brain volume changes are already on the market, some are even freeware, but only 
a minority of MS centres use it in the clinical routine. It is my opinion that in the next 5 or 10 
year these methods will become mainstream and most probably will be readily available in 
the built-in software of the MRI scans – it’s unavoidable; it’s only a matter of time.   
MRI outcomes were reported by 16.8% of the studies reviewed. However these studies 
combined represent only 4.6% of total patients. A weighted average of 91.6% patients were 
free of T1Gd+ lesions and 73.6% of them were free of new T2 lesions. These numbers are 
consistent or slightly better than the results of the clinical trials. In TRANSFORMS, after one 
year of treatment, 90.1% patients were free of T1Gd+ lesions and 54.8% of them were free 
of new or enlarged T2 lesions. In FREEDOMS and its extension, after 4 years of fingolimod 
treatment 79.5% patients were free of T1Gd+ lesions and 80.9% of them were free of new or 
enlarged T2 lesions. 
Worth to mention is a 50 patient’s study, from Puerto Rico, where it was evaluated the 
number of T1 hypointense lesions and brain atrophy. It was reported 86% patients free of 
new black holes and 90% free of brain volume loss after one year of fingolimod treatment. 
Another study, with 30 patients, evaluated the cortical and subcortical volume 
changes. This study suggests that fingolimod treatment preserves the structural thickness in 
the majority of the brain areas over one year of treatment. 
4.4.6. Composed Outcomes 
I think the natural evolution of MS outcome measures is going from evaluating only 
the clinical outcomes, EDSS and relapses, to focus in the patient as whole and thus 
considering the all 4 measures of NEDA-4. It’s of no use to have a treatment very good at 
reducing the clinical activity, if it does not do much about the imaging outcomes, T2 and 
T1Gd+ lesions and brain volume loss, or vice-versa. The ultimate goal of each and every MS 
treatment should be to achieve Non Evidence of Disease Activity in its 4 dimensions. (Figure 
19) 
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Figure 19 NEDA-4 should be the goal of every DMT 
 
Only 13 studies, representing 4.9% of the patients, have reported composed 
outcomes. Due to the low number of studies reporting most of the composed outcomes, 
these results most be interpreted with caution. (Table 17) 
Table 17. Weighted average of composed outcomes reported 
 
WA Max Min Nr Pts 
Studies 117 306 21 13 1515 
Patients with NTZ as previous treatment 28,2% 100,0% 15,3% 7 741 
Baseline ARR (previous 12 months) 0,64 1,20 0,34 6 606 
Baseline MRI activity 78% 78% 
 
1 100 
Baseline EDSS 2,4 3,9 2,3 6 572 
FU (months) 11,96 16,30 6,00 12 1494 
Free of relapse and T1Gd+ 93,5% 97,3% 89,1% 2 141 
Free of EDDS progression and MRI activity 42% 42% 42% 1 37 
Free of relapse and MRI activity 68,8% 87,6% 47,6% 3 504 
Free of relapse and EDSS progression 66,6% 79,7% 56,3% 7 770 
Free of relapse, EDDS progression and MRI activity 62,5% 72,5% 50,3% 3 419 
WA – Weighted Average; Max – Maximum; Min – Minimum; Nr – Number of studies; PTS – Number of patients 
Only two of the composed outcome measures reported can be compared with data 
from the clinical trials. (Table 18) With the exception of Free of EDSS progression and MRI 
activity, which was only reported by one study, fingolimod achieved a good proportion of 
patients free of activity in all the other composed outcomes. This reinforces the 
effectiveness of fingolimod in the clinical practice.  
  
89 
 
Table 18. Composed outcomes of pivotal trials 
 
FREEDOMS 
2 years 
 TRANSFORMS 
1 year 
 
Patients 425  429  
Mean Follow-up (months) 24  12  
Baseline ARR (previous 12 months) 1.5  1.5  
Baseline EDSS 2.24  2.2  
Free of relapse and EDSS progression 62%  79%  
Free of relapse, EDDS progression and MRI activity 33%  46%  
4.4.7. PRO, FDO and Other outcomes 
4.4.7.1. Persistence 
Persistence and adherence are very important factors to the effectiveness of any 
treatment, because even with a very efficacious treatment it is of no use if the patients 
discontinue treatment, or do not adhere to the recommended posology. 
Table 19. Studies excluded from the weighted average calculation 
Cohort Patients 
FU 
(months) 
Persistence [Adherence] 
Gilenya* Go 
Program(TM) 
1700 
 
85.5% 
Tokyo 44 
 
75% 
MSBase Registry 148 11 
Persistence on FTY was better compared to 
DMT (hazard ratio 0.39) 
Granada 42 
 
98% 
Multicenter1 Spain 101 
 
96% 
Santiago de 
Compostela 
143 
 
99.4% 
Wimbledon 305 
 
84.59% 
Boston 
  
Adherence [MPR 75.4% (NTZ 79%)] 
FU – Follow-Up; FTY – fingolimod; DMT – Disease Modifying Treatment; MPR – Medication Possession Rate; 
NTZ – natalizumab 
 
Persistence/adherence was reported by 46.3% of the studies, which observed a total 
of 18,471 patients. To calculate the weighted average, 8 studies were excluded because 
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either the persistence was not reported in a way compatible with the calculation, or because 
the study did not report the follow up period. The weighted average, considering both 
patient numbers and follow-up duration, was 82.8%, after 11.6 months of follow-up. 
4.4.7.2. Patient and neurologist reported outcomes 
The impact of a chronic, debilitating disease as MS goes beyond its impact on patient’s 
physiology, and is of utmost importance to give the deserved relevance to other outcomes 
that are also important, like quality of life, treatment satisfaction, work productivity, 
cognition, impact on family and care givers, etc. Unfortunately most pivotal trials do not 
assess this outcomes and that’s where real world evidence can give an important 
contribution to the body of knowledge. 
Montalban et al.264 published one study about the effect of treatment in quality of life 
and depression in the phase II fingolimod trial. This is the only one of its kind and, being a 
randomized, double-blind, placebo-controlled clinical trial, it’s important to look at its 
results, even though the lowest dose used was 1.25mg, in contrast with the approved 0.5mg. 
After 6 months of treatment it was possible to observe an improvement in the reported 
quality of life in fingolimod treated patients and a deterioration in the placebo arm (1.25mg 
vs placebo, p= 0.044), particularly in the fatigue/thinking sub-domain of the Hamburg 
Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS). This study suggests that with 
fingolimod a smaller proportion of patients present signs of clinical depression than with 
placebo (p= 0.0018), even though at baseline there was more fingolimod patients with signs 
of clinical depression. The 24 month extension of this study suggests that this effect can be 
observed in the first 6 month of treatment, and after that the depression symptoms are 
stabilized until month 24. 
Generally speaking fingolimod has a positive impact on patients’ lives, in the domains 
reported by these studies: quality of life, cognition, tolerability, depression, treatment 
satisfaction and fatigue. (Table 20) In these 19 studies, which reported PRO/NRO, a total of 
6,905 patients were followed up. Given the great impact this domains have in patients’ lives 
it is desirable that in the future even more studies look into this.  
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Table 20. Patient and Neurologist Reported Outcomes summary 
Dimension Patients Patients (%)  Studies (%) Results 
Cognition 711 2,3%  2,1% 2/2 positive 
Depression 1609 5,2%  7,4% 2/7 neutral; 5/7 positive 
Fatigue 790 2,5%  1,1% 1/1 positive 
QoL 6136 19,7%  7,4% 2/7 neutral; 5/7 positive 
Tolerability 4021 12,9%  2,1% 2/2 positive 
Treatment Satisfaction 1382 4,4%  4,2% 4/4 positive 
QoL – Quality of Life 
4.4.7.3. First Dose Observation 
The transient cardiovascular effects of the first fingolimod dose were reported by 
25.3% of the studies, which enrolled 16,683 patients. The first dose of fingolimod was 
uneventful in a big proportion of patients, usually > 90%, and most of the patients (≈95%) 
were discharged after the 6 hour observation period. In clinical trials it was reported 4.7% 
incidence of first degree AV block and <0.2% of second degree AV block. 
FIRST208 was a 2,417 patient open-label multicentre study, sponsored by Novartis, to 
assess the overall short-term safety and tolerability of fingolimod 0.5mg.  This study enrolled 
12.2% of patients with cardiac risk and 5% treated with calcium channel blockers and/or 
beta blockers. A Mobitz type I second-degree atrioventricular block was found in 4.1% 
patients before the first dose administration. In the group without cardiac risk there was an 
incidence of new events post-dose of 1.1% and this incidence was 4.0% in the group with 
cardiac risk.  
An Italian study,199  with 112 patients found that 20.1% patients showed abnormalities 
in the baseline ECG, including a first-degree atrioventricular block in 0.9% of patients. There 
was 1.8% of de novo first degree AV block and 0.9% of de novo second degree AV block. 
4.4.7.4. Other outcomes 
A 12 month follow up study of 55 Italian patients reported that active patients had 
more relapses before fingolimod (p= 0.043), a lower mean white blood cell count (p = 0.027) 
and a lower mean lymphocyte count (p = 0.05) compared to disease-free patients. The 
authors’ hypothesis is that "protective" cell subsets maybe also affected by the excessive 
lymphopenia.191 
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One Italian study, with 35 patients, focused on fingolimod effect on headache and 
reported 2.9% of de novo headache. Headache was reported in 23-25% of patients in the 
phase III clinical trials, but there is no reference to the baseline incidence.203 
Retinal and macular volume effects of fingolimod were the focus of two American 
studies, with 232 and 126 patients.241,256 In the Cleveland Clinical study wasn’t possible to 
detect a change in macular volume, but a small increase in central subfoveal thickness and 
outer retina thickness was detected. The study from Seattle reported a decrease in macular 
volume (p=0.003).  Both studies reported a trend of ganglion cell/internal plexiform layer 
and retinal nerve fibre layer thinning. It can be speculated that these changes maybe disease 
and/or treatment related, thus further studies with a control arm would be helpful to clarify 
how much of these effects can be attributable to fingolimod. 
4.4.8. Natalizumab Switch 
Given that natalizumab patients have a risk of developing PML, especially after 24 
months of treatment;265 it is common to switch these patients to fingolimod, as a therapy of 
similar efficacy. Natalizumab patients are usually in a more advanced state of disease, than 
patients previously treated with first line DMTs. So it is expectable to get results that aren’t 
as good as when fingolimod is used in a DMT switch population. 
Around 20% of studies focused on the natalizumab switch strategy. Many strategies 
have been employed (Table 21) and the review of these studies suggests that the switch to 
fingolimod is the most successful strategy, even though it is not in this population that we 
can observe fingolimod’s best results.  
Table 21. Natalizumab switch strategies used in these studies 
Natalizumab switch strategies 
Different washout periods from 0 to 52 weeks 
Washout period with monthly methylprednisolone 
Fingolimod as subsequent treatment 
DMTs as subsequent treatment 
Other immunomodulating agents as subsequent treatment 
No treatment after natalizumab 
 
EDSS values greater than 3, washout period length and ARR (pre-treatment and during 
natalizumab treatment) have been proposed as predictors for relapses post-natalizumab, 
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but probably due to the small samples, it has been impossible to achieve significant results 
across several studies. The washout period length seems to be the most consensual 
predictor. 
The studies reviewed suggest that in a significant number of patients after natalizumab 
interruption disease activity goes to pre-natalizumab levels in the first 6 months. The 
majority of studies recommend a maximum washout period of 6 to 12 weeks. In most 
studies, a shorter washout was associated with a lower risk of disease reactivation. 
Fingolimod in these studies has shown to be able to control disease reactivation in most 
patients. It can be speculated that patients previously treated with natalizumab are, for 
obvious reasons, in a more advanced disease level, when the diffuse damage starts to be 
relatively more important than the focal damage, even though the two coexists. This 
hypothesis could explain both the inefficacy of first line DMTs, which only act on the 
inflammation (focal damage); and the efficacy of fingolimod, which has a double mechanism 
of action, acting upon the immune system, reducing the focal damage, and directly in the 
central nervous system reducing the diffuse damage. 
In this population, even though it’s not easy to reach a conclusion, fingolimod seems to 
avoid a reactivation of disease in most patients.  
4.4.9. Safety Outcomes 
Safety issues, even more than efficacy outcomes, suffer from a great variability in the 
way they are reported. In the 7 cohorts analysed, 145 different AEs were identified, but 
some appear twice in the list if in one study was classified as AE and in another study was 
classified as SAE. In 77.9% of the AEs/SAEs, the incidence reported in the clinical trials was 
superior or similar to the reported incidence in the studies reviewed. Generally, the real 
world practice confirms the safety profile already established in the clinical trials.  
In the first dose of fingolimod a short-term and asymptomatic heart rate decrease can 
be observed in most cases. The studies reviewed confirm the findings in the clinical trials for 
the cardiovascular AEs44,266, with only a small number of events, reported in more than one 
of these studies, being unheard before. In Table 22 can be found a summary of the 
cardiovascular AEs not reported or reported with higher incidence than in clinical trials. 
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Table 22. CV AEs not reported or reported with higher incidence than in clinical trials 
AE Incidence in individual  studies Incidence in all studies 
Angina pectoris 0.0% (1) 0.009% 
Blood pressure decreased 0.6% 0.04% 
Cardiac flutter 0.3% 0.02% 
Heart rate decrease 1.4% 0.1% 
Palpitations 1.5%; 0.6% 0.24% 
QT interval prolongation 0.7% 0.11% 
Sinus bradycardia 0.0% (1); 1.0% 0.08% 
Tachycardia 0.1% 0.02% 
Thromboembolic events 0.9%; 0.5% 0.20% 
Ventricular extra systoles 0.2% 0.05% 
Pulmonary oedema 0.1% 0.015% 
Incidence in all studies was calculated by dividing the number of reports in the study, by the total population 
enrolled in the reviewed studies for safety outcomes 
 
Asymptomatic ALT and bilirubin increases were reported mostly in the first months of 
fingolimod treatment in clinical trials. After treatment interruption, the enzymes returned to 
normal levels within 6 months.44,267 The reviewed studies reported also other liver function 
changes, which are summarized in Table 23. Once more, the different ways of reporting 
these AEs, make it difficult to make a comparison between studies.  
Table 23. Liver function AEs not reported in clinical trials with these designations 
AE 
Incidence in individual  
studies 
Incidence in all studies 
Liver disorder 1.5% 0.11% 
Liver dysfunction 6.5% 0.48% 
Liver enzyme elevation 3.5% 0.45% 
γ-glutamyltransferase increased 1.8%; 3.9%; 1.1% 0.70% 
Incidence in all studies was calculated by dividing the number of reports in the study, by the total population 
enrolled in the reviewed studies for safety outcomes 
 
Macular oedema was reported in 0.6% patients in clinical trials44, mostly in the first 6 
months of treatment, and in most cases with recovery after treatment interruption without 
the need of macular oedema treatment. The macular oedema incidence reported in all 
studies was 0.32%, and it was calculated by dividing the number of reports in the study, by 
the total population enrolled in the reviewed studies for safety outcomes.  
Fingolimod overall incidence of infections and serious infections was similar to placebo 
in clinical trials, with lower respiratory tract infections being the only type of infections with 
slightly higher incidence than placebo44. The reviewed studies confirmed this infection 
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profile. Worth to mention are the incidences in all studies (calculated by dividing the number 
of reports in the study, by the total population enrolled in the reviewed studies for safety 
outcomes) of reactivation of chronic viral infections (0.79%) and Herpes zoster infections 
(0.25% vs 3.1% reported in clinical trials44). 
Fingolimod mechanism of action involves the selective and reversible retention of 
lymphocytes in secondary lymphoid organs, thus having an impact in the serum 
quantification of these cells. Because the different studies may have used different 
thresholds and ways of reporting, it’s useful to present these differences in Table 24. In 
clinical trials it was reported a 73% average decrease in lymphocyte count compared to 
baseline and lymphopenia was reported as an AE in 12% patients44. Leukopenia was 
reported in 2.82% patients in FREEDOMS and 1.6% in TRANSFORMS. 
 
 Table 24. Leukocyte and lymphocytes count changes 
AE Incidence in individual  
studies 
Incidence in all 
studies 
Leukopenia and lymphopenia 6.9% 1.03% 
Lymphocyte count decreased 0.3%; 1.24%; 3.8%; 2.1%; 2.3% 1.21% 
Lymphopenia 6.5% 1.23% 
White blood cell count decreased 8.3% 0.3% 
Incidence in all studies was calculated by dividing the number of reports in the study, by the total population 
enrolled in the reviewed studies for safety outcomes 
 
 
Incidence of malignancies in clinical trials was similar in the fingolimod 0.5mg and in 
the placebo arms. In clinical trials, the Basal Cell Carcinoma (BCC) showed a trend towards a 
bigger incidence with fingolimod 0.5mg than with placebo44. Table 25 summarizes the 
malignancies findings in these studies, which were not reported in clinical trials. Other 
malignancies not shown here had an incidence lower than in clinical trials or have not been 
reported in these studies. Two studies reported only skin cancer, whereas in clinical trials 
skin cancers were classified as BCC or Squamous Cell Carcinoma (SCC). The ratio BCC/SCC  is 
similar to the observed in general population268, and different from the observed in 
immunosuppressed populations269. 
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Table 25. Malignancies not reported in clinical trials 
AE Incidence in individual  studies Incidence in all studies 
Other malignant neoplasms 0.4%; 0.5% 0.12% 
Pancreatic carcinoma 0.1% 0.013% 
Skin cancer 0.7%; 0.1% 0.12% 
Incidence in all studies was calculated by dividing the number of reports in the study, by the total population 
enrolled in the reviewed studies for safety outcomes 
 
Other AEs not reported in clinical trials are summarized in Table 26. The very low 
incidences suggest that it is not probable an association to fingolimod treatment, but time 
will tell. 
Table 26. Other AEs not reported in clinical trials 
AE Incidence in individual  studies Incidence in all studies 
Bronchoconstriction 2.1% 0.31% 
MS symptoms worsening 0.76% 0.12% 
Nephrolithiasis  0.1% 0.01% 
Decreased renal function 0.3% 0.04% 
Itchiness 0.06% 0.01% 
Muscular weakness 1.1% 0.08% 
Physical weariness 1.7% 0.12% 
Pregnancy 0.3% 0.04% 
Reproductive toxicity 0.9% 0.13% 
Incidence in all studies was calculated by dividing the number of reports in the study, by the total population 
enrolled in the reviewed studies for safety outcomes 
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5. Conclusions 
Fingolimod is a small lipophilic molecule, which readily crosses the BBB, and appears to 
have a dual mechanism of action. Its immunomodulatory effect is exerted through the 
selective retention of central memory and naïve T cells in secondary lymphoid tissues, 
preventing their egress to the CNS, where they would cause the focal inflammation 
characteristic of multiple sclerosis.  
The effectiveness of fingolimod in the treatment of Multiple Sclerosis seems to go 
beyond its immunomodulatory effects. Studies in several in vitro and in vivo models have 
shown evidence in favour of a direct neuroprotective function of fingolimod, and results 
from clinical trials are consistent with a mechanism of action that includes direct effects in 
CNS cells, reducing the diffuse damage. Moreover, recent reports in different pathologies 
suggest that fingolimod has neuroprotective effects in several models. 
Fingolimod has proven in an extensive clinical development program its effectiveness 
in reducing relapse rate, disability progression, MRI activity and brain volume loss. In 
FREEDOMS, after 2 years, the likelihood of achieving Non-Evidence of Disease Activity in its 4 
parameters with fingolimod was more than 4-fold higher vs placebo. 
In the clinical development program  fingolimod showed to avoid a higher number of 
relapses. In the long-term, early treatment with fingolimod is associated with lower costs per 
relapse avoided compared with delayed treatment. Under the Portuguese NHS hospital 
perspective, early treatment with fingolimod is expected to result in better clinical outcomes 
associated with a more efficient healthcare resources allocation. 
In clinical practice, patients aren’t as perfect and homogeneous as in clinical trials - 
they have comorbidities, concomitant medications and other idiosyncrasies. Real world 
evidence is very important to answer questions for which clinical trials haven’t looked for 
the answers and to assess treatments’ effectiveness in clinical practice.  
In this review a very broad inclusion criteria was used.   This strategy yields a big 
dataset to work with, but it has the disadvantage of lack of homogeneity that make very 
hard to reach a quantitative conclusion for most variables analysed.  
 
 98 
 
Regarding the ultimate goal of this review, to have an overview of fingolimod 
effectiveness in clinical practice, I think the objective was achieved. The results suggest that 
fingolimod treatment is initiated in a later phase than in clinical trials, in patients with more 
disease duration and higher EDSS score, even though with a lower ARR.  The relapse 
outcomes achieved with fingolimod are pretty much in line of those obtained in clinical 
trials, with an ARR reduction usually above 70%. Fingolimod achieved 90% of patients 
without disability progression after 13.2 months of follow up. In the MRI parameters, 91.6% 
patients were free of T1Gd+ lesions and 73.6% of them were free of new T2 lesions, which is 
a result slightly better than what was seen in clinical trials. Unfortunately a very low number 
of studies reported composed outcomes, but what was reported suggests that fingolimod 
has better results than in clinical trials, having achieved 62.5% patients free of relapse, EDDS 
progression and MRI activity in three studies and 66.6% patients free of relapse and EDDS 
progression in 7 studies.  
In these studies, after 11.6 months 82.6% of patients continue on treatment and 
fingolimod showed a positive impact in patients’ quality of life, cognition, tolerability, 
depression, treatment satisfaction and fatigue. The first dose observation results presented 
no surprises, just confirming what was seen in clinical trials. It was uneventful in a big 
proportion of patients, usually > 90%, and most of the patients (≈95%) were discharged after 
the 6 hour observation period. 
In a final word about efficacy, I would like to address fingolimod results in comparative 
studies with other DMTs and in the natalizumab switch studies. Fingolimod has 
demonstrated superiority in all studies where interferon and/or glatiramer acetate was the 
control, and with DMF, even though the study is too short to reach any reliable conclusion, 
fingolimod was more efficacious. In the studies where natalizumab was used as control, 
fingolimod seems to be, at least as effective as natalizumab when used in second line 
therapy. Fingolimod reported similar or superior results in 50% of the studies. It’s hard to 
reach any firm conclusion because only 25% of these studies reported the proportion of 
patients who had natalizumab as previous treatment, which in two of these studies was as 
high as 50%.  
In the natalizumab switch studies fingolimod seems to avoid a reactivation of disease 
in most patients. And it seems clear that a short natalizumab wash out is associated with 
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better outcomes.  The majority of studies recommend a maximum washout period of 6 to 12 
weeks. 
These studies suggest that fingolimod is well tolerated and with a safety profile that is 
very similar to what was observed on clinical trials. No new safety signals have been 
identified and the AEs which were not reported in clinical trials have a very low incidence.  
To further investigate fingolimod effectiveness in the Portuguese population, I have 
designed and I am now implementing a national observational study sponsored by Novartis 
Farma S.A.. POSITIVE is a 12-month, observational, parallel cohort, multicentre study 
enrolling 152 patients, eligible for treatment with fingolimod or a first line injectable DMT. 
POSITIVE will evaluate treatment adherence and satisfaction, quality of life, work 
productivity; annualized relapse rate and persistence on fingolimod versus first line 
injectable DMTs. Moreover, this study will provide important real-world clinical and patient-
reported outcomes of relevance to early fingolimod therapy. Enrolment will start in 
November 2014; approximately 12 investigational sites across Portugal will recruit patients 
until December 31, 2015. Study results are expected in 2017. 
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6. Final remarks 
 
Part of this work is or will be published in peer reviewed journals. The paper “Central 
effects of fingolimod”, published in Revista de Neurología,  was the final result of a literature 
review done by me and Vitor Cruz.79  
The cost effectiveness analysis was done by me, Daniel Viriato, João Carrasco and 
Ricardo Pacheco and the preliminary results were presented at the Joint ACTIRIMS-ECTRIMS 
Meeting, September 10–13, 2014, Boston, USA136,270 and at ISPOR 17th Annual European 
Congress, November 8-12, 2014, Amsterdam, The Netherlands.271 A more in depth analysis 
and discussion manuscript is being prepared by me, Daniel Viriato, João Carrasco, João 
Fernandes, João Cerqueira, Sofia Oliveira Martins and José Cabrita. This manuscript will be 
submitted on March 2015. 
The results of the real world evidence review of fingolimod will be summarized in a 
manuscript and submitted for publication before April 2015. 
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